The QualityStocks Daily Tuesday, November 23rd, 2021

Today's Top 3 Investment Newsletters

QualityStocks(APVO) $17.0300 +162.81%

MarketClub Analysis(KTTA) $5.6000 +153.39%

SeriousTraders(SNWR) $0.0090 +26.76%

The QualityStocks Daily Stock List

Zion Oil & Gas, Inc. (ZNOG)

We reported earlier on Zion Oil & Gas, Inc. (ZNOG), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Zion Oil & Gas, Inc. operates as an oil and gas exploration company in Israel. It explores for oil and gas onshore in Israel on its 99,000-acre Megiddo-Jezreel license area. Fundamentally, it is exploring for Israel’s Political and Economic Independence. Established in 2000, Zion Oil & Gas has its corporate headquarters in Dallas, Texas. It also has its Israel office in Caesarea. The Company’s shares trade on the OTCQX Best Market.

Zion Oil & Gas’ vision is to find oil and/or natural gas in Israel. The Company’s Founder and Chairman, Mr. John Brown, provides the broad vision and goals for Zion Oil & Gas. The Company says that the initiatives taken by its Management as it explores for oil and gas in Israel are founded on modern science and good business practices. Zion’s oil and gas exploration activities are supported by suitable geological, geophysical, as well as other science-based studies and surveys.

Mr. Brown has wide-ranging management, marketing, and sales experience, serving as Corporate Director of Purchasing at GTE Valeron, a subsidiary of GTE Corporation from 1966 to 1986. He was Corporate Director of Procurement at Magnetek, Inc. during 1988-89. Until 2012, Mr. Brown was also an Officer and Director of M&B Holding, Inc.

Zion Oil & Gas previously announced the departure of a drilling rig and equipment from Constanta, Romania and en route to Haifa, Israel. The Company expected the rig to reach the port of Haifa, Israel by November 13, 2020. Upon customs clearance, the crew was scheduled to satisfy certain protocols required by Israel, and, without unforeseen circumstances, Zion Oil & Gas expects to spud the Megiddo-Jezreel #2 well at its present well location near Bet She'an by early to mid-December 2020. The Company said that there is an aggressive drilling schedule planned on the Megiddo-Jezreel #2 (MJ02) well location.

Zion Oil & Gas, Inc. (ZNOG), closed Tuesday's trading session at $0.19405, up 43.5281%, on 14,515,280 volume with 2,241 trades. The average volume for the last 3 months is 14.515M and the stock's 52-week low/high is $0.111/$1.74.

DroneGuarder, Inc. (DRNG)

QualityStocks, OTCtipReporter, PennyStockProphet, Small Cap Firm, Penny Pick Finders, PennyStockScholar, Epic Stock Picks, StockOnion, Profitable Trader Authority, PennyStockLocks, Fortune Stock Alerts, Penny Stock 101, Buzz Stocks, PennyPickAlerts, Wolf of Penny Stocks, StockRockandRoll, Penny Stock Titans, Penny Picks, PoliticsAndMyPortfolio, Stock Beast, Juicy Penny Stocks, Investors Alley, InvestorPlace, Wall Street Mover and Damn Good Penny Picks reported earlier on DroneGuarder, Inc. (DRNG), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

DroneGuarder, Inc.  centers on commercializing a drone enhanced home security system as a turnkey solution. The design of its DroneGuarder Mobile App  is to let users have peace of mind within arms length, whether they are in their home or not. Established in San Francisco in 2017,  DroneGuarder has its head office in London, England.  

The Company’s solution is app-based. It includes a drone, infrared camera, and an Android mobile app component. Upon an alarm being triggered, the DroneGuarder™ will immediately take off from a wireless charging pad.  

The DroneGuarder™ assists in protecting against intruders. Upon an intruder being detected on the sensor net,  one can have the drone fly to the event location. Once there,  one can use the built-in microphone to issue a harsh warning to scare away intruders. If that fails, the high-quality HD film captured of the intruder can be uploaded to the cloud and forwarded to law enforcement agencies.  

A variety of DJI drones is available and compatible with the DroneGuarder system. The design of the drones is to respond to commands from a user’s smart phone, and its native remote. This enables one to give it basic orders from anywhere.

DroneGuarder uses Swellpro as its drone supplier. DroneGuarder’s intention is to work jointly to embed its scanning AI image recognition technology into Swellpro’s SD5 drone platform. This will enable the DG Rescue to autonomously grid search for victims in a search area and alert the rescue crews through GPS location and streaming video where the victims are. DroneGuarder will be jointly developing DG Intruder with Swellpro using all the same technology, however it will be app based.

DroneGuarder previously launched its DG App on Google Play. The Company is enhancing the functionality for login and flight control including autonomously and controlled security sweeps. DroneGuarder also secured new funding, which enables the Company to fund DG Rescue and DG Intruder product developments through to commercial release.

DroneGuarder, Inc. (DRNG), closed Tuesday's trading session at $0.0032, up 23.0769%, on 27,756,586 volume with 192 trades. The average volume for the last 3 months is 27.757M and the stock's 52-week low/high is $0.000182/$0.011727.

Bit Brother (BTB)

QualityStocks and InvestorPlace reported earlier on Bit Brother (BTB), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Bit Brother Limited (NASDAQ: BTB) (FRA: 29D) is a specialty chemical firm that is involved in the production and distribution of organic compounds.

The firm has its headquarters in Changsha, the People’s Republic of China and was incorporated in 2011, on November 28th. Prior to its name change in May 2021, the firm was known as Urban Tea Inc. It operates as part of the consumer staple products industry, under the consumer staples sector, in the beverages sub-industry.

The company, which is also involved in the specialty tea product retail and distribution business, markets its products through wholly owned subsidiaries. It provides pastries which include frosting cakes, freshly baked cakes and freshly baked bread; light meals like burritos, steak, pasta, sandwiches and salads, as well as other healthy options and tea-based beverages, which include milk cap tea, fruit tea and fresh milk tea, among others. The enterprise also produces para-chlorotoulene (PCT), ortho-chlorotoluene (OCT) and unsaturated polyester resin (UPR) products. UPR products can be used in manufacturing materials for trains, cars, aircrafts and vessels. Its organic compounds are used in the food additive, clean energy, coating-printing, ceramics, aerospace, dye and pigments, agrochemical, pharmaceutical and automotive industries.

The enterprise plans to acquire a share of Angelo’s Pizza 1697 Inc., which has been around for over a century. This move will have a positive effect on the growth of both companies and allow Bit Brother to actualize its plans to expand into a restaurant while it continues to grow its Bitcoin payment business.

Bit Brother (BTB), closed Tuesday's trading session at $0.9885, up 15.3442%, on 22,675,400 volume with 38,300 trades. The average volume for the last 3 months is 22.675M and the stock's 52-week low/high is $0.7421/$6.6924.

MediciNova (MNOV)

StockMarketWatch, MarketBeat, StockOodles, QualityStocks, IRGnews Alert, Wall Street Resources, The Street, BUYINS.NET, MarketClub Analysis, Schaeffer's, DrStockPick, CRWEPicks, CRWEWallStreet, PennyToBuck, CRWEFinance, INO.com Market Report, BestOtc, PennyOmega, Promotion Stock Secrets, StockHotTips, StreetInsider, TradersPro, OTCPicks, WiseAlerts, Greenbackers, FreeRealTime, Wallstreetlivechat and Weekly Wizards reported earlier on MediciNova (MNOV), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

MediciNova Inc. (NASDAQ: MNOV) (FRA: RMN) is a biopharmaceutical firm that is engaged in the development of new small molecule therapies for treating severe ailments with unmet medical needs in the U.S.

The firm has its headquarters in La Jolla, California and was incorporated in 2000, on September 26th by Yuichi Iwaki. It operates in the health care sector, under the biotech and pharma sub-industry and provides its products to the healthcare industry in the U.S. market.

The enterprise is party to a collaboration agreement with Mie University and BioComo which entails jointly developing a vaccine for the virus that causes the coronavirus, SARS-CoV-2.

The company’s product pipeline is made up of clinical-stage compounds for treating solid tumor cancers, interstitial cystitis, asthma, neuropathic pain, meth addiction, progressive multiple sclerosis, COPD and acute exacerbations of asthma. Its formulations include a tubulin binding agent dubbed denibulin (MN-029) indicated for the treatment of solid tumor cancers; an orally bioavailable compound known as tipelukast (MN-001) indicated for the treatment of fibrotic illnesses, which include idiopathic pulmonary fibrosis and non-alcoholic steatohepatitis and a selective beta-2-adrenergic receptor agonist dubbed bedoradrine (MN-221) developed to treat acute exacerbations of asthma. In addition to this, the company also develops an oral neuroprotective and anti-inflammatory agent known an ibudilast (MN-166) which has been indicated for the treatment of substance dependence and addiction, glioblastoma, degenerative cervical myelopathy, chemotherapy-induced peripheral neuropathy, amyotrophic lateral sclerosis, and secondary and primary progressive multiple sclerosis.

The firm recently announced positive results from its MN-166 candidate phase 2 clinical trial in treating alcohol use disorder, noting that the formulation showed great potential in reducing the growing problem of alcohol use disorder. The effects of the coronavirus pandemic led to increased stress and anxiety, which prompted a surge in alcohol misuse and alcohol use disorder. The commercialization and use of this treatment once it obtains approval from the FDA will help extend the firm’s consumer reach and boost growth.

MediciNova (MNOV), closed Tuesday's trading session at $4.42, up 43.9739%, on 17,565,394 volume with 61,480 trades. The average volume for the last 3 months is 17.565M and the stock's 52-week low/high is $3.03/$10.81.

Sun Pacific Holding (SNPW)

QualityStocks, OTCBB Journal, Broad Street, Today's Stock Tip, StocksImpossible, StockRockandRoll, StockHideout, Small Cap Firm, PennyStockLocks, Penny Stock 101, OTC Stock Review, MegaPennyStocks and Awesome Stock Tips reported earlier on Sun Pacific Holding (SNPW), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Sun Pacific Holding Corp. (OTC: SNPW) is a green energy firm that is focused on the provision of solar panel and lighting products in the U.S. It is engaged in the designing, development, building and management of green technologies.

The company was founded in 2009 and has its headquarters in Manalapan, New Jersey. Prior to its name change, the company was known as EXOlifestyle Inc. and operates as part of the electrical, plumbing and hardware wholesalers’ industry.

The firm is focused on using its experiences and capabilities in green energy solutions to help transform neighborhoods across the nation into smart cities. Its subsidiaries include Sun Pacific Security Corp., National Mechanical Corp., Bella Electrical LLC, Street Smart Outdoor Corp. and Sun Pacific Power Corp.

It provides advertising space on solar trash bins, solar digital shelters, bus benches and bus shelters, through one of its subsidiaries. Additionally, the firm offers plumbing, electrical and general contracting services to commercial and public customers. It is also engaged in the construction and development of a waste to energy plant in the state of Rhode Island. The firm’s energy lighting solutions and solar power bus shelters provide customers with turnkey systems.

The enterprise has a solid foundation which will aid in the growth of the company in a responsible and focused manner. In addition to this, the company is working on building valuable relationships and is set to expand into international markets through various partnerships and collaborations, with one of them entailing the development of a high efficiency off grid digital plug and play modular unit.

Sun Pacific Holding (SNPW), closed Tuesday's trading session at $0.0274, up 125.5144%, on 179,084,335 volume with 4,268 trades. The average volume for the last 3 months is 178.964M and the stock's 52-week low/high is $0.0011/$0.349.

Iconic Brands, Inc. (ICNB)

Bloomfield Investment Club, QualityStocks, SmallCapVoice, AwesomeStocks, OTCPicks, DSR News, BestDamnPennyStocks, CoolPennyStocks, Global Equity Report, Nebula Stocks, 24-7 Stock Alert, Penny Invest, Penny Stock Hub, TheNextBigTrade, PHUB News, MicroStockProfit, AlphaTrade, Beacon Equity Research, The Observer, StockEgg, Broad Street, Stock Rich, Damn Good Penny Picks, smartOTC, Small Cap Firm, OtcWizard, Light Speed Stocks, Penny Stock Professor, Monster Stock Alerts, Morning Stock Picks, PREPUMP STOCKS, OTCBB Journal, PennyTrader Publisher, TopPennyStockMovers, Penny Picks, Penny Stock Explosion, PennyStockRumors.net, Penny Stock Newsletter and HotOTC reported earlier on Iconic Brands, Inc. (ICNB), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Iconic Brands, Inc. is a beverage company listed on the OTC Markets Group’s OTCQB. The Company’s expertise is developing, from inception to completion, alcoholic beverages for itself and third parties. It markets and places products into national distribution via long standing industry relationships. Iconic Brands offers wine and distilled alcoholic beverages, and also liquor based products infused with hemp and CBD. The Company is headquartered in Amityville, New York.

Iconic Brands is a leader in Celebrity and Private Label beverages. It obtains first-rate and innovative products from around the world and brands its products with globally recognized celebrities and corporate icons. The Company’s corporate mission is to be the industry leader in brand development, marketing, and sales of the highest quality alcoholic beverages.

Iconic Brands is under contract with United Spirits - a federally-licensed importer and distributor of alcoholic beverages. In addition, the Company is under contract with Mr. Dan Kay, who maintains a New York State warehousing license for alcoholic beverages.

Regarding Services, Iconic Brands’ takes a customer’s product idea from concept to completion. This includes everything from sourcing, flavor profiles, packaging, design, marketing and distribution. Iconic an also align a customer’s brand with select celebrity endorsement. Iconic markets its products under the Bivi, Bellissima, Bella, and Romano brand names.

Recently, Iconic Brands announced it entered into a Letter of Intent (LOI) to acquire recently formed Green Grow Farms, Inc. Green Grow Farms partners directly with farmers to transition their crops to hemp for the purpose of extracting Cannabidiol (CBD Isolate/Oil). It provides full support services and logistics to take product from seed to sale.

Iconic Brands also announced that Green Grow Farms secured a processor and material supplier agreement with one of the largest vertical Hemp processors in the world. The agreement is for an initial 2-year term. It allows for a minimum of 2 million pounds of biomass to be processed to CBD isolate, and sold under a revenue sharing agreement. With average CBD percentage and processing efficiency rates from Green Grow’s farming operations, two million pounds should process into roughly 40,000 kilograms of CBD Isolate.

Additionally, Iconic Brands, in conjunction with its Licensed Partner, United Spirits, announced the introduction of Hooters Spirits, with the official debut at this year’s WSWA Conference. Hooters Spirits is a private label brand for Hooters of America, the iconic restaurant chain. The product portfolio comprises Hooters Vodka, Hooters Gin, Hooters Rum, Hooters Tequila, Hooters American Whiskey and Hooters Shooter, a cinnamon flavored whiskey.

Iconic Brands, Inc. (ICNB), closed Tuesday's trading session at $0.85, up 14.962%, on 503,104 volume with 410 trades. The average volume for the last 3 months is 503,104 and the stock's 52-week low/high is $0.091/$1.00.

Simplicity Esports and Gaming Company (WINR)

QualityStocks, StockMarketWatch, StreetInsider, InvestorPlace and BUYINS.NET reported earlier on Simplicity Esports and Gaming Company (WINR), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

OTCQB-listed, Simplicity Esports and Gaming Company is an established brand in the esports industry. The Company has an engaged fan base competing in popular games across diverse genres. These include PUBG, Fortnite, League of Legends, Overwatch, Gears of War, Smite, and numerous EA Sports titles. The Company formerly went by the name Smaaash Entertainment, Inc. It changed its corporate name to Simplicity Esports and Gaming Company in January of 2019. Incorporated in 2017, Simplicity Esports and Gaming is based in New York, New York.

The Company also operates Esports Gaming Centers. These provide the public an opportunity to experience and enjoy gaming and esports in a social setting, regardless of skill or experience. In essence, Simplicity Esports and Gaming is a global virtual reality gaming and completely integrated eSports platform business. The Company expects to have 85 esports gaming centers by the end of this calendar year.

It is an emerging operator and developer of family entertainment centers throughout the United States, combining proprietary sports, eSports, virtual and augmented reality gaming, and also dining into a highly interactive and innovative social experience for family and friends. The Company’s totally integrated eSports platform concept will include the development of dedicated eSports centers across the nation, alongside the management of eSports teams at all competitive levels.

In 2019, Simplicity Esports and Gaming Company acquired PLAYlive Nation, Inc. PLAYlive has a network of 44 franchised Gaming Centers across 11 States, including but not limited to, California, Washington, Arizona, and Texas, serving more than 150,000 unique gamers yearly. PLAYlive Centers are highly complementary to Simplicity Esports Gaming Centers, which offer gamers a specialized entertainment gaming experience within a social setting.

Simplicity Esports and Gaming announced that it created a new, majority owned subsidiary and acquired all of the assets of PL Gaming Texas LLC, one of the most successful franchisee-owned esports gaming centers in its nationwide footprint. Simplicity Esports also executed a lease assignment and amendment with the landlord that does not require a specified fixed rent, but instead determines rent as a percentage of gross sales.

Mr. Roman Franklin, President of Simplicity Esports and Gaming, stated, “Our franchisee has done an excellent job building, staffing, and growing this location. The gaming center consists of over 30 gaming stations, gaming related merchandise and accessories for sale, and a quality staff that will remain in place after the acquisition to continue serving the center’s thousands of existing customers. The percentage rent lease structure gives us the necessary flexibility to navigate COVID-19 related impacts on customer traffic counts by reducing fixed costs.”

Simplicity Esports and Gaming Company (WINR), closed Tuesday's trading session at $8.09, up 24.4615%, on 5,778 volume with 23 trades. The average volume for the last 3 months is 5,778 and the stock's 52-week low/high is $5.56/$22.00.

Nano Dimension Ltd (NNDM)

RedChip, MarketClub Analysis, Schaeffer's, StockMarketWatch, MarketBeat, InvestorPlace, TradersPro, The Street, QualityStocks, TraderPower, BUYINS.NET, Trades Of The Day, Buzz Stocks, Daily Market Beat, Planet Penny Stocks, OTCBB Journal, Daily Trade Alert, InvestorsUnderground, OTCtipReporter, Penny Pick Finders, Broad Street, PennyStockScholar, Wealth Insider Alert, Profitable Trader Authority, StockOnion, The Online Investor, Tiny Gems and PennyStockProphet reported earlier on Nano Dimension Ltd (NNDM), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Nano Dimension Ltd (NASDAQ: NNDM) (FRA: 2N5B) is engaged in the provision of additive electronics internationally.

The firm has its headquarters in Ness Ziona, Israel and was incorporated in 2012. It operates as part of the electronics and appliance stores industry. The firm has seven companies in its corporate family.

The company is focused on developing a 3-D printer that prints electronic circuit boards and other additively manufactured electronics. It is targeting the increasing demand for electronic devices which rely on printed circuit boards, antennas and encapsulated sensors and need sophisticated features. Geographically, it derives most of its revenue from the United States, followed by Israel, Europe and the Asia Pacific. The company markets and sells its services and products to firms which develop products with electronic components, including firms in the medical, aerospace, semiconductor, consumer electronics, automotive and defense industries, as well as research institutes.

The enterprise’s products include its DragonFly LDM system (lights-out digital manufacturing system), which produces professional conductive geometries, sensors, radio frequency antennas, multilayer circuit boards and molded connected devices for prototyping via custom additive manufacturing. It also offers its Switch and DragonFly software to manage the printing and design file process. This is in addition to offering nanotechnology-based dielectric and conductive inks.

The firm recently entered into an agreement to acquire Essemtec AG, whose product portfolio comprises of production equipment used to assemble electronic components on printed circuit boards. This move will help extend its consumer reach and bring in more investors into the firm, which will be good for its growth.

Nano Dimension Ltd (NNDM), closed Tuesday's trading session at $4.62, even for the day, on 7,215,524 volume with 31,100 trades. The average volume for the last 3 months is 7.102M and the stock's 52-week low/high is $4.45/$17.89.

AIM ImmunoTech (AIM)

StockMarketWatch, BUYINS.NET, Kiplinger Today, TradersPro, MarketClub Analysis, InvestorPlace, QualityStocks, StreetInsider, Wall Street Resources, SmallCapVoice, MarketBeat, Profitable Trader Authority, Buzz Stocks, Investor Ideas, Investors Alley, OTCtipReporter, Penny Pick Finders, PennyStockScholar, Stock Stars, StockOnion, Street Insider, Vantage Wire and PennyStockProphet reported earlier on AIM ImmunoTech (AIM), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

AIM ImmunoTech Inc. (NYSE American: AIM) (FRA: HXB2) is an immune-pharma firm that is engaged in researching and developing therapeutics for the treatment of different cancer types and immune-deficiency disorders.

The firm has its headquarters in Ocala, Florida and was incorporated in 1990. Prior to its name change in August 2019, the firm was known as Hemispherx Biopharma Inc. It serves consumers in the United States.

The company is focused on a business plan oriented toward finding senior co-development parties with the expertise and capital required to commercialize the potential therapeutic aspects of its formulations. It is party to agreements with the University of Cagliari, Polysciences Inc., Shionogi & Co. Ltd, Japanese National Institute of Infectious Diseases, and UMN Pharma Inc.

The enterprise’s product pipeline comprises of a natural alpha interferon injectable formulation known as Alferon N Injection, which is indicated for the treatment of a sexually transmitted infection known as genital warts; and a macromolecular ribonucleic acid molecule drug dubbed Ampligen, which has been developed to treat chronic fatigue syndrome. In addition to this, its Ampligen formulation is indicated for the treatment of myalgic encephalomyelitis, prostate and pancreatic cancer, colorectal, breast ovarian, non-small cell lung, malignant melanoma and renal cell carcinoma cancers, HIV and Hepatitis B.

The company is focused on advancing trials and activities that have the shortest path to potential EMA and FDA drug approval, offering opportunities for expedited success. This may also bring in more opportunities for investment and additional revenues into the company, which will be good for its growth.

AIM ImmunoTech (AIM), closed Tuesday's trading session at $1.29, off by 3.7313%, on 924,111 volume with 2,445 trades. The average volume for the last 3 months is 922,891 and the stock's 52-week low/high is $1.11/$3.06.

Aptevo Therapeutics (APVO)

StockMarketWatch, MarketBeat, TraderPower, StreetInsider, TradersPro, MarketClub Analysis, Stock Beast, QualityStocks, Promotion Stock Secrets, Marketbeat.com and BUYINS.NET reported earlier on Aptevo Therapeutics (APVO), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Aptevo Therapeutics Inc. (NASDAQ: APVO) (OTC: APVTW) (FRA: AP8N) is a clinical-stage biotechnology firm that is engaged in the development of immunotherapeutic candidates for treating different forms of cancer.

The firm has its headquarters in Seattle, Washington and was incorporated in 2016, on February 22nd. It operates as part of the pharmaceutical and medicine manufacturing industry, under the healthcare sector. The firm has three companies in its corporate family and serves consumers in the United States.

The company offers hematology and oncology therapeutics. It is party to an option and collaboration agreement with Alligator Biosciences AB, which entails the development of its ALG. APV-527 formulation.

The enterprise’s product pipeline comprises of a dual agonist bispecific antibody dubbed APVO603 which targets OX40 and CD137; and an investigational bispecific APAPTIR candidate known as ALG.APV-527 which features a mechanism of action which targets CD137 and a tumor antigen expressed in different types of cancers known as 5T4. It also develops a bispecific candidate known as APVO442, which improves the bio-distribution of drugs to PSMA positive tumors for treating prostate cancer. In addition to this, the enterprise also develops a bispecific T-cell engaging antibody candidate dubbed APVO436, which is undergoing a phase 1 clinical trial evaluating its effectiveness in treating myelodysplastic syndrome and acute myelogenous leukemia.

The firm seeks to improve the treatment outcomes of cancer patients. Currently, it is focused on receiving data from its APVO436 phase 1b expansion trial, which has the potential to impact the existing standard of care for acute myeloid leukemia.

Aptevo Therapeutics (APVO), closed Tuesday's trading session at $17.03, up 162.8086%, on 164,120,486 volume with 889,390 trades. The average volume for the last 3 months is 161.273M and the stock's 52-week low/high is $6.38/$51.7499.

Innoviz Technologies (INVZ)

InvestorPlace, Trades Of The Day, MarketBeat and Daily Trade Alert reported earlier on Innoviz Technologies (INVZ), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Innoviz Technologies Ltd (NASDAQ: INVZ) is focused on the development of perception software which facilitates the production of autonomous vehicles, as well as designing and manufacturing solid state LiDAR sensors.

The firm has its headquarters in Rosh Haayin, Israel and was incorporated in 2016, on January 18th by Oren Rosenzweig, Oren Buskila and Omer David Keilaf. It primarily serves consumers in Israel.

The company provides perception software and LiDAR sensors which allow for safe autonomy by bringing cutting-edge software, seamless design and unparalleled optics to market. It operates in North America, Africa, the Middle East and Europe.

The enterprise’s products include a LiDAR sensor dubbed InnovizOne, which has been designed for delivery, trucking, shuttle, robotaxi and automaker firms which require a mass-producible and automotive-grade solution to achieve autonomy. It also offers an automotive-grade LiDAR sensor known as InnovizTwo, which provides a solution for all autonomous driving levels. This sensor also provides an option to integrate the perception application in the LiDAR sensor. In addition to this, it offers a software application which turns the InnovizOne raw point cloud data into perception outputs to offer superior scene perception. The enterprise’s products can be used in different industries, which include the robotics, construction, maritime, mining, security, smart city and agriculture industries.

The company is uniquely positioned to secure new design wins because of its extensive automotive experience, its portfolio of products and growing capabilities. It is focused on solidifying its position as the leading LiDAR supplier in the automotive industry.

Innoviz Technologies (INVZ), closed Tuesday's trading session at $7.07, off by 3.6785%, on 2,875,193 volume with 17,950 trades. The average volume for the last 3 months is 2.875M and the stock's 52-week low/high is $4.40/$12.50.

Mammoth Energy Services (TUSK)

MarketBeat, StreetInsider, The Online Investor, StockMarketWatch, TradersPro, Zacks, The Street, smallcapstreet, OTCBB Journal, InvestorsObserver Team, Energy & Resources Digest, Daily Market Beat, BUYINS.NET and Broad Street reported earlier on Mammoth Energy Services (TUSK), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Mammoth Energy Services Inc. (NASDAQ: TUSK) (FRA: 5M8) is an oilfield service firm that is focused on exploring for and developing North American onshore unconventional natural gas and oil reserves.

The firm has its headquarters in Oklahoma City, Oklahoma and was incorporated in 2016, on June 3rd. It serves co-operative utilities, public and private investor owned utilities, government-funded utilities, independent natural gas and oil producers and land-based drilling contractors in North America.

The company operates through the drilling, natural sand proppant services, well completion services and infrastructure services segments. The drilling segment provides rig moving services, directional and contract land drilling services, while the well completion segment offers high-pressure hydraulic fracturing services to improve the production of natural gas and oil from formations with low permeability. On the other hand, the natural sand segment is focused on offering logistics solutions to aid in the delivery of frac sand products; purchasing processed sand from suppliers then reselling that sand; and mining, processing and selling proppant for hydraulic fracturing. The infrastructure segment provides various services on electric transmission and distribution, substation and networks facilities, which include commercial services like installing, maintaining and repairing of commercial wiring; storm restoration and repair services; and construction, maintenance and repair of high voltage transmission lines. In addition to this, the company also provides a range of energy services, which include remote accommodation, crude oil hauling, equipment rental, aviation and full-service transportation services.

The enterprise is focused on improving its results as it moves further into the infrastructure space, in order to enhance sustainability and long-term growth.

Mammoth Energy Services (TUSK), closed Tuesday's trading session at $1.81, off by 11.2745%, on 786,417 volume with 2,954 trades. The average volume for the last 3 months is 784,162 and the stock's 52-week low/high is $1.76/$7.27.

The QualityStocks Company Corner

FingerMotion Inc. (OTCQX: FNGR)

The QualityStocks Daily Newsletter would like to spotlight FingerMotion Inc. (OTCQX: FNGR) .

FingerMotion (OTCQX: FNGR), a mobile data and services company, held its annual meeting of stockholders on Nov. 22, 2021. During the meeting, several key issues were ratified by company stockholders and implemented by FNGR’s board of directors. Those issues included the election of Hsien Loong Wong, Leong Yew Poh, Michael Chan and Ng Eng Ho to FingerMotion’s board of directors and the appointment of Centurion ZD CPA & Co. as the company's independent registered public accounting firm. In addition, stockholders approved FNGR’s 2021 stock incentive plan and executive compensation. Finally, following the meeting, several company executive officers were reappointed to the board of directors, including FNGR president and CEO Martin Shen and chief financial officer, secretary and treasurer Yew Hon Lee. To view the full press release, visit https://ibn.fm/JV5vB

FingerMotion Inc. (OTCQX: FNGR) is an evolving technological company with core competencies in mobile payment and recharge platform solutions in China. FingerMotion is in the process of developing additional value-added technologies to market to users.

Founded in 2016, FingerMotion’s goal is to serve over a billion users in the Chinese market and expand its model to other regional markets. The company has offices in Hong Kong, Shanghai and New York City.

Current Offerings

FingerMotion is analyzing and transforming mobile data to improve the lifestyle of the public through technology and innovation. The company’s current offerings include:

  • Telecommunications Products and Services – FingerMotion’s proprietary universal exchange platform, ‘PigeonHole Integration System (PIS)’, offers seamless integration between telecom operators and online stores. The service platform’s offerings include top up and recharge, data plan, mobile phone, loyalty points redemption and subscription plans. The platform offers reliable and secure transactions, real-time reconciliation, simple integration for partners and efficient settlements.
  • SMS and MMS Services – The integrated platform is registered as FingerMotion’s IP in China and provides a robust back-end control panel for corporate partners to manage their own messaging settings. FingerMotion’s clients range from insurance to financial industries, ecommerce firms, airlines and more. The platform offers competitive pricing for partners and provides quick and efficient review to meet timely marketing initiatives.
  • Big Data Insights – FingerMotion brings Big Data-enabled insurance solutions through its Big Data Insights arm, Sapientus. The company’s strategic partnerships with the largest Chinese telecommunications giants allow access to uncover behavior insights through geolocation and mobile data usage. Its Big Data offerings include risk scoring, precise marketing, simplified underwriting and customized products.
  • Rich Communication Services (RCS) – FingerMotion’s RCS platform will be a proprietary business messaging solution that enables businesses and brands to communicate their services to customers via 5G infrastructure. The company expects its RCS platform to offer a better user experience, more efficiency and cost-effectiveness when compared to other solutions.

Telecommunications and Insurtech Markets

The global telecommunications market was valued at $1.74 trillion in 2019 and is expected to grow at a CAGR of 5% from 2020 to 2027. The steady increase is expected to be driven by the adoption of 5G and the increased popularity of Internet of Things (IoT) applications.

The Chinese telecom market was valued at $254.1 billion in 2017 and is also constantly expanding. The current Chinese telecom market is dominated by three mobile operators – China Mobile, China Unicom and China Telecom, which together are responsible for around 1.6 billion active subscribers (https://ibn.fm/zfwy9).

In addition, the insurtech (insurance technology) market was valued at $2.72 billion globally in 2020 and is expected to grow at a CAGR of 48.8% from 2021 to 2028. The large increase is attributed to the rising use of technology solutions for everyday activities like acquiring insurance coverage (https://ibn.fm/TGo7D).

Through its proprietary platforms and technologies, FingerMotion is uniquely positioned to capitalize on the telecom and insurtech markets’ growth and opportunities.

Management Team

Martin J. Shen is the Chief Executive Officer of FingerMotion Inc. He has over 15 years of experience in senior management roles within entrepreneurial startups and large multinational corporations. He has acquired a wide range of corporate management, financial oversight and operation administration expertise through these roles. In his most recent role, he founded Imperial Distributors (formerly known as AP Martin Pharmaceutical Supplies Ltd.), establishing the company as the preferred choice for distributional support to regional pharmacies throughout Western Canada. Before founding Imperial, Mr. Shen served as the Chief Operating Officer and Chief Financial Officer at Wales and Son Industrial (formerly Weir Minerals), a firm specializing in global delivery and support for mining slurry equipment. He began his career at PricewaterhouseCoopers in Vancouver, with work tours in the tax department in Singapore and the tax audit and advisory group in Hong Kong. Mr. Shen is a U.S. Certified Public Accountant and holds a Bachelor of Science from the University of British Columbia.

Lee Yew Hon is the company’s Chief Financial Officer. From 2006 until November 2020, he was the Chief Financial Officer of Cubinet Interactive Group of Companies, and he also took on the Chief Operating Officer role in 2011. During his tenure, he was instrumental in leading Cubinet and building teams across the Southeast Asia region, setting up financial processes within a short time. Mr. Lee spearheaded the growth of Cubinet to other regions, including Europe, the Middle East and Russia. He received his diploma from Tunku Abdul Rahman College in 1996. He is a Chartered Accountant, a member of the Malaysia Institute of Accountants (MIA) and an Associate Member of the Chartered Institute of Management Accountants, UK (ACMA).

Li Li is the Senior Vice President of FingerMotion. She recently served as Advisor to Shenzhen WuYiKa Technology Co. Ltd., a comprehensive service platform dedicated to online service distribution and payment. The company has become a fast and efficient provider of new media marketing solutions for the mobile internet. She has held high-level management positions with multiple industry names, including Hangzhou JiuYue Information Technology Co. Ltd. and Hangzhou LingXuan Information Technology. Ms. Li started her career in 2004, founding Shanghai ChuangYeZZ Network Technology Co. Ltd. and serving as its Vice President. With the close cooperation of local operators, the company launched SMS, MMS, WAP, mobile JAVA games, Hunan Satellite TV e-magazine and other wireless internet services to meet the rapid development of wireless internet and application requirements. She received her degree from Nanjing Academy of Engineering.

FingerMotion Inc. (FNGR), closed Tuesday's trading session at $6.28, up 7.9038%, on 13,069 volume with 51 trades. The average volume for the last 3 months is 13,017 and the stock's 52-week low/high is $3.22/$17.00.

Recent News

BevCanna Enterprises Inc. (CSE: BEV) (OTCQB: BVNNF) (FSE: 7BC)

The QualityStocks Daily Newsletter would like to spotlight BevCanna Enterprises Inc. (CSE: BEV) (OTCQB: BVNNF) (FSE: 7BC).

BevCanna Enterprises (CSE: BEV) (OTCQB: BVNNF) (FSE: 7BC), an emerging leader in innovative health and wellness beverages and products, today announced that TRACE will be the exclusive water partner for Country Music Week 2021. Hosted by the Canadian Country Music Association(R) (“CCMA”) in London, Ontario, from Nov. 26-29, 2021, the event will celebrate country music in Canada and culminate with the 2021 CCMA Awards Show to be broadcast in a live special on Nov. 29, 2021. TRACE will keep fans, artists and the Canadian country music industry hydrated in its capacity as the exclusive water partner of Country Music Week 2021 and the 2021 CCMA Awards. “We’re thrilled to partner with the CCMA on providing TRACE alkaline water for Country Music Week 2021 and the 2021 CCMA Awards,” said Melise Panetta, president of BevCanna. “As we continue to focus on expanding national awareness of TRACE product, this is an excellent opportunity for us to reach Canadian country music fans — a growing demographic that is a strong fit for the TRACE brand.” To view the full press release, visit: https://ibn.fm/Awh8h

BevCanna Enterprises Inc. (CSE: BEV) (OTCQB: BVNNF) (FSE: 7BC) is a diversified health & wellness beverage and natural products company focused on developing and manufacturing a range of plant-based and cannabinoid beverages and supplements for both in-house brands and white-label clients. The BevCanna team boasts decades of experience creating, manufacturing and distributing iconic brands that resonate with consumers on a global scale.

BevCanna’s distribution network features more than 3,000 points of retail distribution through the company’s market-leading TRACE brand, its Pure Therapy natural health and wellness e-commerce platform, its fully licensed Canadian cannabis manufacturing and distribution network and its partnership with #1 U.S. cannabis beverage company Keef Brands.

Based in British Columbia, Canada, BevCanna was founded in 2017.

End-to-End Turnkey Beverage Manufacturing Solutions

BevCanna is a manufacturer of traditional and cannabis-infused beverage brands serving a growing roster of white-label clients, in addition to operating a portfolio of in-house and partner brands. The company offers a full-service white label beverage manufacturing solution.

  • Processing – At its state-of-the-art beverage manufacturing facility, BevCanna partners with industry leaders specializing in crude extraction, refinement, purification and solubility conversion to provide high-quality water-immiscible emulsions that maximize bioavailability, clarity and taste.
  • Spring Water – BevCanna directly owns a pristine naturally alkaline spring water aquifer in British Columbia.
  • Product Development – BevCanna leverages its expertise to develop captivating flavors based on category and consumer insights in order to enhance product positioning.
  • Packaging – A variety of packaging options are offered by BevCanna, including beverage and nutraceutical formats such as PET, aluminum and glass, available in a variety of standard and custom sizes and shapes.
  • Beverage Manufacturing: Traditional & Cannabis Facilities – The company’s 40,000-square-foot beverage manufacturing facility is HACCP (Hazard Analysis Critical Control Point) Certified. The facility’s capabilities include blow molding, dosing, carbonation options, filling and capping, pressure sensitive and shrink-sleeve label applications, flash pasteurization, QA testing and packing/palletizing for shipment.

Pure Therapy, TRACE and Partner Brands

BevCanna’s in-house brands include Pure Therapy and TRACE.

Pure Therapy is a direct-to-consumer e-commerce brand that markets a range of natural health products, including nutraceuticals and hemp-based cannabidiol (CBD) products, throughout North America and Western Europe.

Pure Therapy has secured orders from over 23,000 customers since its inception in 2017. BevCanna expects strong growth through Pure Therapy over the next 12 months driven by new product integration, accelerated growth of existing products and its marketing team’s e-commerce expertise.

TRACE products feature the Naturo Group’s proprietary plant-based fulvic and humic mineral formula, sourced from deep within the Rocky Mountains of interior British Columbia. These unique and ancient minerals provide wellness properties that include iron, magnesium, calcium, potassium and many other minerals no longer found in our food chain at adequate levels.

Research suggests that the proprietary fulvic and humic organic compounds found in TRACE products could offer a number of key benefits, including promoting gut health, immune function, cognitive performance and whole-body wellness.

TRACE products include Natural Alkaline Spring Water, Plant-Based Mineralized Spring Water, Natural Flavor Sparkling Spring Water, Plant-Based Mineral Concentrate with Vitamin D and Plant-Based Mineralized Immune Support Shots.

In addition to its in-house brands, BevCanna provides white-label services to a number of partners in its space. BevCanna’s current portfolio of brand partnerships includes #1 U.S. cannabis beverage brand Keef (cannabis-infused classic soda) and BLOOM (live resin & high-end extracts). BevCanna also has multiple white label agreements to co-manufacture branded beverages.

Market Outlook for Cannabis-Infused Beverages

In 2018, the cannabis-infused beverage market was valued at $901.8 million. The market is expected to grow during the forecast period of 2019 to 2025 at a CAGR of 17.8%, resulting in a market value in excess of $2.84 billion by 2025, according to Grand View Research (https://ibn.fm/VkJfH).

The projected growth is largely attributed to the legalization of recreational and medical marijuana in multiple jurisdictions. Cannabis-infused beverages are uniquely positioned to provide an alternative to a large portion of the edibles market, including items such as chocolates, cookies, gummies and other types of confectionery pieces.

Management Team

Marcello Leone is the CEO and Founder of BevCanna. He is also the founder of Naturo Group and the TRACE brand.

John Campbell is the CFO and CSO of BevCanna. He has over 30 years of experience in the investment industry, including time with TriView Capital Ltd.

Keith Dolo is the company’s Executive Management Advisor, having previously served as CEO and Executive Chairman of Sproutly Inc. Previously, he served for over 13 years with Robert Half (NYSE: RHI), an S&P 500 company, specifically in the role of Vice President for the last eight years.

Melise Panetta is the company’s President. She is an accomplished senior marketing and sales executive with extensive experience leading organizations such as SC Johnson, General Mills (NYSE: GIS) and PepsiCo (NASDAQ: PEP). Ms. Panetta has nearly 15 years of deep marketing and sales expertise.

Raffael Kapusty is the company’s Vice President of Sales & Insights. She is an accomplished CPG industry leader with more than 25 years of experience in both the Canadian and U.S. retail spaces. With a solid foundation at ACNielsen Canada (NYSE: NLSN), Ms. Kapusty has developed a deep understanding of the CPG space, working with over 100 leading Canadian & global CPG manufacturers. She has also held senior category and key account management roles at Kroger (NYSE: KR), SC Johnson and Unilever Canada (NYSE: UL).

Bill Niarchos is the company’s Vice President of Sales & Sales Operations. He has over 20 years of experience in the CPG goods industry/retail environment. In his most recent role as Director of Sales with Bayer Consumer Health, Mr. Niarchos managed the strategic direction and growth of Loblaw & SDM. Prior to his position with Bayer (ETR: BAYN), Mr. Niarchos held a number of progressive roles at Colgate Palmolive (NYSE: CL) for more than 14 years.

Japheth Noah is the company’s Head of Quality Assurance. He is an Oxford and MIT educated quality and regulatory manager with over 15 years of experience in the beverage, pharmaceutical, natural health and medical industries.

Keith Stride is the company’s Creative Director. He has 25 years of experience in marketing and advertising, including time in a CMO role with Hemptown USA. Mr. Stride is internationally recognized for building high-profile brands, including Rogers (NYSE: RCI), TD Bank (NYSE: TD), Best Buy (NYSE: BBY), Whistler-Blackcomb and RBC (NYSE: RY).

BevCanna Enterprises Inc. (OTCQB: BVNNF), closed Tuesday's trading session at $0.207, up 1.4706%, on 34,434 volume with 25 trades. The average volume for the last 3 months is 34,434 and the stock's 52-week low/high is $0.172/$1.20.

Recent News

Flora Growth Corp. (NASDAQ: FLGC)

The QualityStocks Daily Newsletter would like to spotlight Flora Growth Corp. (NASDAQ: FLGC).

Many veterans believe that plant-based medicines are a much better option for treatment in comparison with opioids, which are easily addictive. However, most are having trouble accessing medical cannabis, even in states where medical use of the herb is legal. Currently, 36 states in the country have established medical marijuana programs while 18 states have legalized the recreational use of cannabis; in addition Guam, the Northern Mariana Islands and the District of Columbia have legalized the substance. Despite the existence of these programs, physicians at VA Medical Centers aren’t allowed to prescribe this plant-based medicine. In addition, Stearman noted that the biggest worry was the uncertainty around what would happen with an individual’s relationship with their physician, their pain management plan and their benefits with Veterans Affairs if they began to use medical marijuana. This situation is unfortunate, given the high-quality medicinal products that are readily available in legal markets where companies such as Flora Growth Corp. (NASDAQ: FLGC) operate.

Flora Growth Corp. (NASDAQ: FLGC) is an internationally focused cannabis brand builder that leverages natural, cost-effective cultivation practices to supply cannabis derivatives to its diverse business divisions, including cosmetics, hemp textiles, and food and beverage. Flora Growth operates one of the largest outdoor cultivation facilities in the world with an aim of marketing a higher-quality premium product at below-market prices. By prioritizing natural ingredients and value-chain sustainability across its portfolio, the company creates premium products that help consumers restore and thrive.

Flora Growth completed the first traditional cannabis IPO on Nasdaq in May 2021. Although currently headquartered in Toronto, Ontario, with plans to relocate its head office to Miami, Florida, the company’s base of operations is in Colombia, where it has built an extensive distribution network that includes Colombia’s largest distributors.

Currently, Flora Growth is organically growing market share for its existing brand portfolio (pharmaceuticals, textiles, cosmetics, and food & beverage) while seeking revenue-generating acquisitions that offer an accretive distribution network to amplify revenue growth.

Existing Brand & Product Portfolio

Flora Growth’s portfolio spans a number of verticals – each with a thoughtful brand designed to resonate with its intended end consumer. In line with the company’s mission, each brand prioritizes natural ingredients and value-chain sustainability.

Flora Lab S.A.S

Flora Lab is the company’s GMP certified manufacturing and R&D center focused on producing pharmaceuticals, cosmetics, and nutraceuticals for domestic and international markets. Its offerings include product lines that are private label, white-label, and custom formulas.

Through Flora Lab, Flora Growth has relationships with 1,500+ distribution channels, manufactures 63+ OTC products registered with INVIMA (Colombia National Food and Drug Surveillance Institute), and holds multiple GMP certifications enabling international export in an effort to leverage Flora Lab’s capacity to produce a wide range of CBD-infused products.

Flora Beauty

Flora Beauty is the company’s CBD beauty and cosmetics division founded by fashion and beauty industry icon Paulina Vega. Its current offerings include two CBD skincare brands targeting the U.S. and Latin American markets – MIND NATURALS and AWE. These lines exemplify Flora Growth’s socially conscious approach to business.

Currently, Flora Beauty products are offered globally through e-commerce, as well as through Falabella’s 111 retail locations across Latin America. The company is in negotiations with major department stores to launch the line in the U.S. and is also exploring opportunities in the U.K. and other European markets.

KASA Wholefoods

KASA Wholefoods is a Colombian manufacturer of food and beverages leveraging responsibly sourced exotic fruits from the Amazon. KASA has a $10 million+ distribution agreement with Tropi, Colombia’s largest food distributor, which has 130,000+ distribution points across the country.

Mambe, KASA’s leading brand, is already offered through over 980 distribution points across Colombia. Flora Growth expects this network to grow to over 1,200 distribution points in 2021, including one of Colombia’s largest coffee chains, Tostao Café & Pan.

Hemp Textiles & Co.

Through its Hemp Textiles division, Flora Growth intends to utilize its large land package and cultivation infrastructure to capture market share in the rapidly growing hemp industrials segment.

The company’s first brand through this division, Stardog Loungewear, offers a line of comfortable loungewear made from natural, organic materials. Stardog has been distributing globally through e-commerce and brick and mortar channels in Bogota since fall 2020, and the company intends to open U.S. brick and mortar locations in 2021.

Accretive M&A

Flora Growth is targeting transactions to complete the supply chain via key infrastructure to enhance its global distribution with the aim to compete on low-cost, high-quality inputs paired with premium brands that create business lines with robust margins.

To date, Flora has announced two major transactions.

Koch & Gsell (Acquisition)

  • Amplify CPG portfolio’s revenue growth through leading brand, Heimat, currently with TTM revenues of $7.6 million.
  • Leverage Koch &Gsell’s distribution network of 2,500+ stores to introduce Flora to the Swiss, European and Asian markets.
  • Bring patented hemp cigarette manufacturing technology into new markets utilizing Flora’s high-quality cannabis.

Hoshi International (Investment)

  • Equity Investment of €2 million into Hoshi to establish Flora as a preferred supplier to two EU processing facilities.
  • Opens gateway for Flora Growth’s cannabis through international distribution agreements in the EU and U.K.
  • Hoshi’s experienced team and increased access to the EU cannabis market to serve as a catalyst for revenue growth.

Cultivation

Key to Flora Growth’s expansion efforts is its cultivation strategy. The company’s Cosechemos farm, located in Bucaramanga, Colombia, is currently licensed to cultivate 247 acres of cannabis. Through three successful pilot crop plantings, the location has demonstrated a production cost of just $0.06/gram. For comparison, the average cost of North American cannabis (based on 2019 figures from Aphria, Tilray, Sundial, and Aurora) equates to roughly $1.89/gram.
Flora Growth is uniquely positioned to capitalize on Colombia’s favorable growing conditions, low-cost infrastructure, and affordable local workforce as it looks to ramp up its cultivation efforts moving forward.

Leadership Team

Bernard Wilson is the Chairman of Flora Growth. A senior financial professional, Dr. Wilson is the former Vice-Chairman of PricewaterhouseCoopers LLP and is the Chairman of the Founders Board of the Institute of Corporate Directors. He has also served as Chairman of the Canadian Chamber of Commerce; Chairman of the International Chamber of Commerce – Canada; and Member of the Canada/U.S. Trade Committee. Dr. Wilson draws on this experience to ensure Flora Growth adheres to effective corporate governance practices.

Luis Merchan is the company’s President and CEO. He is a proven executive with over a decade of experience in enterprise sales management, corporate strategy, merchandising and expense management, and customer experience. Mr. Merchan previously served as Macy’s Inc.’s Vice President of Workforce Strategy and Operations, where he managed the enterprise’s multi-billion-dollar P&L expense line for the entire 540 store portfolio. Throughout his tenure at Macy’s, he led various sales and marketing initiatives, including the B2B corporate sales team that was responsible for $160 million in annual revenue. Mr. Merchan obtained his Bachelor of Industrial Engineering from Pontifical Xaverian University in Bogota, Colombia, and his MBA from McNeese State University. He also holds a Graduate Certificate in Marketing Management from Harvard.

Juan Manuel Galan is a Strategic Advisor to the Flora Growth management team. Mr. Galan currently serves as a senior consultant to The World Bank. He is a politician and former senator of Colombia, serving three terms from 2006 to 2018 as a member of the Colombian Liberal Party. He is also a former professor at the University of Rosario and holds more than 20 years of journalistic, academic, governmental and parliamentary experience. During his time as a senator, Mr. Galan was a key leader, with 29 bills and 27 debates on political control, and 17 laws to his name. The most relevant of those laws was authoring the medical cannabis law that resulted in the legalization of medical cannabis in Colombia.

Stan Bharti is a Director of Flora Growth. Mr. Bharti currently serves as Executive Chairman of Forbes & Manhattan. He has more than 30 years of professional experience in business, finance, markets, operations and more, with a focus on the resource and technology sectors. To date, Mr. Bharti has amassed over $3 billion worth of investment capital for the companies with which he has worked and their shareholders. He is a Professional Mining Engineer and holds a master’s degree in engineering from Moscow, Russia, and University of London, England.

Javier Franco is the company’s VP of Agriculture. Mr. Franco is a master horticulturist with more than 25 years of experience in the design, implementation, and management of cultivation and propagation facilities of more than 30 species of cut flowers in Latin America. He completed his agricultural studies at Zamorano University in Honduras and later at an International Exchange Program at Ohio State University. Mr. Franco has directed technical, commercial, and research groups in the cut flower, fruit and vegetable markets in Latin America and has participated in the commercial development of new technologies applied in agribusiness. He has also led the agri-management of organic crops and certifications of Good Agricultural Practices.

Flora Growth Corp. (FLGC), closed Tuesday's trading session at $2.16, up 1.4085%, on 1,632,326 volume with 7,591 trades. The average volume for the last 3 months is 1.544M and the stock's 52-week low/high is $2.0302/$21.45.

Recent News

Mullen Automotive Inc. (NASDAQ: MULN)

The QualityStocks Daily Newsletter would like to spotlight Mullen Automotive Inc. (MULN).

Electric vehicles (“EVs”) are poised to play a significant role in transportation as several countries across the world pledge to cut their carbon emissions and mitigate the effects of climate change. Unlike internal combustion engine (“ICE”) cars, EVs are powered by a rechargeable battery coupled with electric motors and produce zero emissions at the tailpipe. However, as automakers ramp up the development of electric cars, there have been claims about electric grids being unable to handle an influx of EVs. Electric car batteries can store significant amounts of energy, and some are worried that as more people switch to EVs, the extra energy needed to keep them running may place undue stress on the electric grid. Electric vehicle makers such as Mullen Automotive Inc. (NASDAQ: MULN) are also constantly looking to improve battery technology, so a time may come when a single charge may last longer than is currently possible, thereby further reducing the strain on power grids.

Mullen Automotive Inc. (NASDAQ: MULN) is a Southern California-based automotive company that owns and partners with several synergistic businesses working toward the unified goal of creating clean and scalable energy solutions. Mullen has evolved over the past decade in sync with consumers and technology trends. Today, the company is working diligently to provide exciting EV options built entirely in the United States and made to fit perfectly into the American consumer’s life. Mullen strives to make EVs more accessible than ever by building an end-to-end ecosystem that takes care of all aspects of EV ownership.

Commencement of Trading on Nasdaq

On November 5, 2021, Mullen announced its commencement of trading on the Nasdaq Capital Market.

“Today is a monumental day for Mullen Automotive. I am especially proud of our team, investors and all who have believed in Mullen and taken us to this point as a publicly traded company on the Nasdaq Capital Market,” David Michery, CEO and Chairman of Mullen Automotive, stated in the news release. “Trading on Nasdaq now opens us up to new investors, both institutional and retail shareholders, and broadens our awareness and company profile, while increasing awareness of Mullen and our technology platform and opening new opportunities in EV and beyond. The road ahead has never been brighter for Mullen, and I am proud to lead us into the future.”

The milestone came in the wake of the company’s stock-for-stock merger with Net Element Inc.

The Mullen FIVE

The Mullen FIVE EV Crossover, debuting at the Los Angeles International Auto Show (LAIAS) on November 17, 2021, embodies Mullen’s Southern California roots with an inspired design focused on two complementary Golden State themes – California landscape and California urban.

The FIVE is built on an EV Crossover skateboard platform that offers multiple powertrain configurations and trim levels in a svelte design that is Strikingly Different™ and exciting to experience in person.

Prior to the start of LAIAS, the Mullen FIVE was selected as a finalist by the LA Auto Show for Top EV SUV in the ZEVA “People’s Choice” Awards.

LAIAS provides Mullen an opportunity to display multiple variants of the FIVE model while also showcasing its powertrain, battery and charging technology. The company intends to bring the FIVE to market in 2024, and reservations are currently open here.

Mullen’s development portfolio also includes EV Fleet Vans, which it intends to bring to market in Q2 2022, and the pure electric, high performance Mullen DragonFLY.

Expansion of Manufacturing Capacity

On November 2, 2021, Mullen announced plans to expand its facility in Robinsonville, Mississippi.

Mullen’s Advanced Manufacturing and Engineering Facility (AMEC) currently occupies 124,000 square feet of manufacturing space. The total available land on the property is over 100 acres, and Mullen is moving ahead with plans to build out another 1.2 million square feet of manufacturing space to support class 1 and class 2 EV cargo vans and the Mullen FIVE EV Crossover.

On the expanded site, Mullen plans to build a body shop, a fully automated paint shop and a general assembly shop.

EV Market Outlook

The global EV market was reported to consist of 3,269,671 units in 2019, a figure that is expected to grow at a CAGR of 21.1% through 2030 to a total of 26,951,318 units worldwide. This market’s monetary value was estimated at $162.34 billion in 2019 and is expected to grow at a CAGR of 22.6%, resulting in an approximate value of $802.81 billion by 2027. The primary driver for this exponential growth is a worldwide increase in vehicle emissions regulations.

Management Team

David Michery is the CEO and Founder of Mullen and has been leading the company and its divisions since inception in 2014. With over 25 years of executive management, marketing, distressed assets, and business restructuring experience, Mr. Michery brings a wealth of relevant knowledge and expertise to the Mullen brand. He has notably created 12 trademarks so far to develop the company brand and vision.

Mr. Michery is working toward a sustainable future accessible to all by creating a suite of clean-energy electric vehicles at varied price points. With entirely U.S.-based manufacturing and operations, he is also determined to have Mullen Technologies play a role in shaping a self-sustaining local economy by creating more jobs in America.

Mr. Michery manages risks and company expectations as a pathway to success and has personally overseen several businesses that totaled over $1 billion in transactions. His key strength is the ability to be fiscally responsible and lead teams to complete projects on time and within budget. As a seasoned professional in this space, Mr. Michery has demonstrated skill in building businesses from the ground up and into successful entities that subsequently sold for hundreds of millions of dollars.

Mullen Automotive Inc. (MULN), closed Tuesday's trading session at $8.71, up 2.9551%, on 976,097 volume with 5,982 trades. The average volume for the last 3 months is 971,001 and the stock's 52-week low/high is $6.95/$19.15.

Recent News

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF)

The QualityStocks Daily Newsletter would like to spotlight Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF).

A new study has found that psilocybin-assisted psychotherapy increases neural and cognitive flexibility in patients suffering from major depressive disorder. Psilocybin is the active compound found in hallucinogenic mushrooms. Research has found that the component has clinically substantial and long-lasting effects on mood and personality when used in conjunction with psychotherapy. The study was published in “Translational Psychiatry,” with researchers suggesting that psychedelic-induced increases in neural flexibility don’t always translate into cognitive improvements. Studies have pointed out that psilocybin has immense therapeutic potential. Therefore, it is no surprise that many companies, including Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF), are in various stages of developing and commercializing medicines from this psychedelic and others.

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) is a pharmaceutical company focused on developing clinical-stage compounds for diseases with high unmet medical needs through accelerated regulatory pathways.

The company was founded in 2019 and is headquartered in San Diego, California.

Innovative Drug Pipeline

Tryp’s current focus is on advancing its two drug development platforms: its Psilocybin-for-Neuropsychiatric Disorders (PFN™) program targeting fibromyalgia, eating disorders and chronic pain conditions; and razoxane for soft tissue sarcomas. The company intends to explore opportunities to monetize these platforms after generating Phase 2b clinical data.

The company’s development plans cover three strategic initiatives:

  • Develop: Tryp intends to utilize the FDA’s 505(b)(2) regulatory pathway with available third-party preclinical data to shorten the timelines and lower the cost of its development programs.
  • Protect: Tryp plans to utilize regulatory exclusivity, patents, trade secrets and proprietary know-how to protect the commercial lifespan of its drug candidates.
  • Monetize: Tryp intends to seek out licensing, acquisition and co-development opportunities for drug candidates following their Phase 2 stages of development.

PFN™ Program

Through its PFN™ program, the company is focused on developing psilocybin-based drug therapies for certain neuropsychiatric disorders that have distinct advantages over other drugs currently on the market or in development. These advantages include:

  • Increased efficacy
  • Natural blood-brain barrier penetration
  • Enhanced safety and toxicity profiles
  • Reduced risk of abuse
  • Reduced risk of addiction

Tryp’s PFN™ program features its lead drug candidate, TRP-8802. The company’s initial indication for TRP-8802 is fibromyalgia.

Fibromyalgia is believed to be a neurosensory disorder characterized in part by abnormalities in pain processing by the central nervous system. The three drugs with FDA approval for the treatment of fibromyalgia are Pregabalin (Lyrica®), Duloxetine (Cymbalta®) and Milnacipran (Savella®), which are only effective for a portion of patients suffering from the condition.

Tryp plans to seek FDA approval to proceed directly to Phase 2 clinical trials evaluating TRP-8802 as a treatment for fibromyalgia based on existing preclinical and clinical data for the active pharmaceutical ingredients in TRP-8802.

Tryp’s pipeline of indications for TRP-8802 also includes eating disorders and certain forms of chronic pain. The company expects to initiate Phase 2a clinical trials in these areas in 2021.

Tryp recently partnered with Albany Molecular Research Inc. (“AMRI”) for the manufacture of the company’s synthetic psilocybin using proprietary methods. AMRI has initiated the process of manufacturing a 200g non-GMP demonstration batch of psilocybin and will produce a batch of GMP psilocybin in mid-2021. As the holder of the Drug Master File, Tryp expects to be the only U.S.-based manufacturer of synthetic psilocybin in the industry.

Razoxane

Tryp’s second drug candidate, TRP-1001 (razoxane), is being developed as a treatment for soft tissue sarcomas and has been evaluated in multiple Phase 2 clinical trials conducted by clinicians unaffiliated with Tryp. The company believes that existing clinical data regarding razoxane will likely allow TRP-1001 to be studied in a Phase 2 trial without the need for extensive preclinical or Phase 1 trials.

Sarcomas are rare tumors that are derived from connective tissues in the body and comprise 7% of all cancers in children. In 2018, an estimated 13,000 new cases of soft tissue sarcoma were diagnosed, with the tumors resulting in over 5,000 deaths during that year in the United States alone (https://ibn.fm/nWOGq).

Market Outlook

With its drug development programs targeting multiple indications, Tryp is well positioned to capitalize on growth opportunities spanning a range of therapeutic markets. The global oncology drugs market, in particular, represents a sizable opportunity.

In 2018, oncology indications accounted for 25% of all drug sales, representing approximately $151 billion in market revenues. By 2024, spending on oncology-targeted therapeutics is expected to top $200 billion and account for roughly 30% of total drug sales, according to a study by Cowen Equity Research (https://ibn.fm/9iZhM).

Valued at $764 million in 2020, the global fibromyalgia treatment market presents unique opportunities for development due to the limited number of approved therapies. With treatment trending upward, the market is expected to grow at a CAGR of 9.2% and reach $1.4 billion in value by 2027 (https://ibn.fm/G66e7).

Management Team

Greg McKee is the Chairman and CEO of Tryp Therapeutics. He has more than 20 years of life sciences management and venture investment experience that he brings to the company. Before taking his role at Tryp, he was the founder of Torrent Ventures, an early-stage digital health and medical technology venture fund. Mr. McKee also served as the CEO of CONNECT, the largest Southern California start-up accelerator. Before this, he was the chairman, president and CEO of then publicly traded Nventa Biopharmaceuticals, which successfully merged with Akela Pharma. Mr. McKee earned a B.A. in Economics from the University of Washington, an M.A. in International Studies from The Joseph H. Lauder Institute, and an MBA from the Wharton School at the University of Pennsylvania. He has been a member of the Young President’s Organization (YPO) since 2006.

James Gilligan, Ph.D., is the company’s President and Chief Science Officer. He has over 35 years of experience in the life sciences industry, including research and development, clinical development, international regulatory affairs and manufacturing. Before joining Tryp, Dr. Gilligan was the Co-Founder and Managing Partner of The Bracken Group, a life sciences consulting firm. He was also the Co-Founder of Unigene Laboratories, which develops technology for the recombinant manufacture of peptide hormones. Dr. Gilligan received his Ph.D. in Pharmacology from the University of Connecticut and a MSIB from Seton Hall University. He continued his post-graduate education at the Roche Institute of Molecular Biology.

Tom D’Orazio is the Chief Operating Officer of Tryp Therapeutics. He has extensive experience in leading the development and commercialization of vaccines, drugs, radiopharmaceuticals and biologics. His prior leadership experience has been in commercial planning, marketing, partnership and business development roles. He was formerly the CEO of ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA), where he led the transition from a private company to a public one. He co-founded and served as CEO of Superna Life Sciences, a specialty-pharma company focusing on niche drugs for cancer patients in Canada. Mr. D’Orazio has an MBA from Vanderbilt University with a primary focus in both finance and marketing and a B.Sc. in chemistry from Loyola University of Chicago.

Luke Hayes is the company’s Chief Financial Officer. He has played an active role in the life science industry for over 20 years with technology transfer, venture capital and finance experience. His career started with business development for Dow Chemical (NYSE: DOW), with responsibility for pharmaceutical customers such as Eli Lilly and AbbVie. Mr. Hayes has spent more than a decade doing venture capital investing while supporting companies as a director and advisor. He earned a B.S. in Chemical Engineering from Brigham Young University and an MBA from the UCLA Anderson School of Management.

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF), closed Tuesday's trading session at $0.2386, up 0.252101%, on 31,960 volume with 33 trades. The average volume for the last 3 months is 31,960 and the stock's 52-week low/high is $0.219/$1.04.

Recent News

Simply Sonoma Inc.

The QualityStocks Daily Newsletter would like to spotlight Simply Sonoma Inc.

Simply Sonoma is positioning itself as a strong player in the global CBD skincare market, which is projected to reach $1.7 billion by 2025, up from $234.1 million in 2018, according to a Million Insights report (https://ibn.fm/csmAb). A recent article, which contains excerpts from the report, notes that CBD-based beauty products are effective and safe for all skin types. “[CBD] is highly beneficial to people who are facing acne, dryness, inflammation and sensitive skin problems,” Million Insights observed. “CBD is used for the skin’s natural healing process and reducing breakouts. It also acts as an antioxidant that helps in reducing early signs of aging and reduces the pain caused by inflammatory skin problems.” As a different kind of natural company, Simply Sonoma is committed to creating high-quality products using organically sun-grown, plant-based ingredients. “Simply Sonoma is looking to leverage its CBD expertise as it develops an organic beauty product line,” reads the recent article. “The company anticipates releasing an array of face and skin creams, moisturizers and beauty products.” To view the full article, visit https://ibn.fm/i4Fcc

Simply Sonoma Inc. produces healthy CBD medicinals and beauty products for the environmentally conscious consumer. The company strives to create the best sustainably grown natural medicinal alternative products and is committed to minimizing its carbon footprint by powering operations off-the-grid using solar energy. Simply Sonoma is creating unique medicinal hemp strains that are alternatives and supplements to traditional, chemically manufactured therapies. The company believes in all-natural, organically sun-grown, plant-based medicinals, and it provides consumers with science-based education on CBD for disease and lifestyle needs.

Simply Sonoma is focused on being a leader in the industry for plant-based medicinal health and beauty products and partnering with like-minded organizations. The company strives to develop broad-spectrum CBD products for therapeutic applications from a scientific perspective. Its products come from the farm rather than from a lab, with the goal of achieving fewer side effects and more efficacy for patients. The company believes in published, science-based trials and research with regard to its CBD creations.

Simply Sonoma is a different kind of natural company. From seed to sale, it owns or contracts the organic grow, extraction and product formulation operations. The company has been developing products since 2017 based on scientific research and data and has several ready to launch. Its nationally available organic CBD products employ the company’s own proprietary formulations.

For example, the company’s nonalcoholic CBD Pinot Noir beverage uses grapes specially grown for Simply Sonoma and is infused with CBD from the company’s farm. The company expects to generate revenue through national sales of its CBD products via e-commerce, as well as through a variety of chain stores, pharmacies and small businesses throughout the U.S.

Products

Simply Sonoma has three tiers of products:

  1. Organic CBD formulations for consumer medicinal applications.
  2. Organic whole plant extracts of CBD and cannabinoids – providing the whole plant synergistic effect and giving a dose response for a variety of diseases.
  3. Organic extracts paired with traditional over-the-counter functionality, delivering all the benefits of traditional OTC products but the bulk product is organic and plant derived for a more natural healthy approach, minimizing synthetic chemical components and adverse effects.

An example of tier three would be the company’s sleep aid. Current over-the-counter and prescription sleep aids like benzodiazepines, antihistamines and sleeping pills disrupt normal sleep brain patterns including REM, resulting in abnormal sleep. CBD and cannabinoids have efficacy as sleep aids and do not disrupt the normal sleep cycle.

Depending on the application, the company’s products can be delivered via:

  1. Teas
  2. Pills
  3. Inhalers
  4. Skin patches
  5. Gummies
  6. Tablets
  7. Sublingual sprays
  8. Tinctures
  9. Topicals
  10. Juices

Simply Sonoma has partnered with Sonoma Biologics, a premium hemp cultivator that has completed considerable research on the scientific nature of hemp and cannabis, to grow proprietary medicinal strains specifically for the company. Additionally, Simply Sonoma is working with Organic Vineyards on the company’s antioxidant, alcohol free, CBD wine product, as well as its low carb, low sugar Pinot Noir CBD sparkling product. All partner companies are environmentally conscious, solar first and organic-equivalent. Simply Sonoma’s CBD products will contain less than 0.3% of THC.

Market Outlook

Simply Sonoma competes with numerous nondescript CBD companies in the market today. The company feels its major competitive advantage is its scientific staff and product formulation expertise. Simply Sonoma products are focused on four specific health, beauty and lifestyle markets, including sleep aids, joint pain, probiotics and skin health. The Market Data Forecast valued the global sleep aid market at an estimated $175 billion in 2020. The joint pain and anti-inflammatory market is forecast to be worth approximately $41 billion in 2026 by Persistence Market Research. The market for gut health and probiotic products is expected to hit $65 billion by 2023, according to Global Market Insights. Allied Market Research valued the global beauty and skin product market at $380 billion in 2019.

Management Team

Simply Sonoma’s dynamic team has a unique combination of experience that positions them well with the company’s wellness and lifestyle products in the CBD space.

Margaret C. Caracciolo is the CEO of Simply Sonoma. She has spent most of her career in biotechnology, in the areas of clinical research and financials. She has worked for notable biotech companies including Heartport, an innovator of heart therapies. She spent time at Aviron, supporting the development of its innovative nasal flu inoculation product, and Genitope, which created personal gene therapies. She has spent the last 10 years co-managing her family’s farm and vineyard and creating wines and other products from the farm’s organic gardens.

Angela Miller is Vice President of Operations at Simply Sonoma. She has extensive experience in cross line-of-business, global project management, and analysis from inception to post-go-live. She spent more than 20 years working at Oracle Corp. and Sun Microsystems Inc., where she obtained expertise in global products, team building, troubleshooting, and customer relations. She also worked seven years with Schwinn Cycling & Fitness, doing everything in the Fitness Division from project management to marketing and public relations.


Recent News

chart

InMed Pharmaceuticals Inc. (NASDAQ: INM)

The QualityStocks Daily Newsletter would like to spotlight InMed Pharmaceuticals Inc. (NASDAQ: INM).

InMed Pharmaceuticals (NASDAQ: INM), a leader in the development, manufacturing and commercialization of rare cannabinoids, will be participating in the 4th annual Cowen Cannabis Conference. InMed’s management team will be presenting in the three-day event, which is scheduled for Nov. 29–Dec. 1, 2021. During the virtual conference, InMed representatives will meet virtually one-on-one with institutional and corporate clients of the firm. The agenda for the annual cannabis conference features topical panel discussions with C-Suite presenters. The event is hosted by Cowen Research and Washington Research Group analysts. To view the full press releases, visit https://ibn.fm/dYIX0

InMed Pharmaceuticals Inc. (NASDAQ: INM) is a global leader in the manufacturing and clinical development of rare cannabinoids. InMed is a clinical stage company developing cannabinoid-based pharmaceutical drug candidates, as well as manufacturing technologies for pharmaceutical-grade rare cannabinoids.

The company is dedicated to delivering new therapeutic alternatives to treat conditions with high unmet medical needs. The company is also developing a proprietary manufacturing technology to produce pharmaceutical-grade rare cannabinoids in the lab and has recently announced an LOI to acquire a leading rare cannabinoid manufacturer.

Research and Technology

There are more than 100 rare cannabinoids found in only trace amounts in the cannabis plant, together making up less than 1% of the plant’s biomass. InMed is initially focused on the therapeutic benefits of cannabinol (CBN) in diseases with high unmet medical need. Preclinical studies of CBN demonstrated an excellent safety profile and showed CBN has potential for therapeutic benefit over other cannabinoids such as tetrahydrocannabinol (THC) and cannabidiol (CBD).

Evidence suggests there may be great therapeutic potential in rare cannabinoids. Each has a specific chemical structure, and different cannabinoids have been observed to have distinct physiological properties in humans, including therapeutic potential for specific diseases as well as unique safety profiles. CBN is the active pharmaceutical ingredient (API) in InMed’s two lead programs for dermatological and ocular diseases.

InMed’s most advanced compound, INM-755, is a CBN topical cream under clinical development for the treatment of epidermolysis bullosa, a severe genetic skin disorder. To date, INM-755 has been evaluated in two Phase 1 clinical trials in healthy volunteers. InMed has filed Clinical Trial Applications in several countries as part of a global Phase 2 clinical trial of INM-755 (cannabinol) cream in epidermolysis bullosa. Responses from the National Competent Authorities and Ethics Committees are expected throughout the summer of 2021.

InMed is also involved in developing INM-088, an ocular CBN formulation being researched for the treatment of glaucoma, the second leading cause of blindness in the developed world. InMed is currently evaluating several formulations to deliver CBN into the eye to address issues of dosing frequency, side effects and treatment penetration. INM-088 is being designed for topical delivery to the eye. This localized delivery results in very little drug being absorbed or migrating into the bloodstream, thus minimizing potential adverse side effects. INM-088 shows promise to reduce intraocular pressure and provide neuroprotection of the eye.

Manufacturing

The limited availability of rare cannabinoids like CBN makes them economically impractical to extract directly from the plant for pharmaceutical use. InMed is developing IntegraSyn, a cannabinoid synthesis manufacturing system to create rare cannabinoids in the lab that are bioidentical to the compounds derived from the cannabis plant. IntegraSyn uses multiple standard pharmaceutical processes and has achieved a cannabinoid yield of 5 grams per liter, surpassing commercial viability and significantly exceeding currently reported industry yields. InMed is now focusing on manufacturing scale-up to larger batch sizes while continuing process optimization, targeting increased cannabinoid yield and further reducing overall cost of goods.

BayMedica Inc. Acquisition

On June 29, 2021, InMed announced it had entered into a non-binding letter of intent to acquire BayMedica Inc., a private company based in Nevada and California that specializes in the manufacture and commercialization of rare cannabinoids.

As noted in the news release, BayMedica is a revenue-stage biotechnology company leveraging its significant expertise in synthetic biology and pharmaceutical chemistry to develop efficient, scalable and proprietary manufacturing approaches to produce high quality, regulatory-compliant rare cannabinoids for consumer applications. BayMedica is currently commercializing the rare cannabinoid CBC (cannabichromene) as a B2B supplier to distributors and manufacturers marketing products in the health and wellness sector. BayMedica is planning additional rare cannabinoid launches for the coming year.

Pursuant to the indicative terms of the LOI, InMed and BayMedica intend to negotiate and enter into a definitive agreement under which InMed would acquire 100% of BayMedica in exchange for 1.6 million InMed common shares to be issued to BayMedica’s equity and convertible debt holders, with any such issued InMed common shares being subject to a six-month contractual hold period.

Market Outlook

There is a rapidly growing demand for rare cannabinoids. However, their low natural concentration makes traditional harvesting of these compounds cost prohibitive. Biosynthesis allows production of rare cannabinoids in the lab that are bioidentical to compounds found in nature, with significantly higher yields which reduce costs. Biosynthesis can produce pharmaceutical-grade, bioidentical, THC-free compounds at a cost that’s 70 to 90 percent less than wholesale prices of naturally harvested rare cannabinoids.

Cannabinoid-based pharmaceuticals are expected to overtake the market as rare cannabinoids become less expensive and more available. According to Statista, the value of the consumer market for cannabinoid-based pharmaceuticals in the United States is forecast to grow to $25 billion by 2025 and to $50 billion by 2029, with cannabinoid-based pharmaceuticals used to treat health conditions including pain, respiratory conditions, autoimmune conditions and more.

Management Team

Eric A. Adams has been CEO and president of InMed since June 2016. He has more than 25 years of experience in establishing corporate entities, capital formation, global market development, mergers and acquisitions, licensing and corporate governance. He previously served as CEO at enGene Inc. Prior to enGene, he held senior positions in global market development with QLT Inc. (Vancouver), Advanced Tissue Sciences Inc. (La Jolla, CA), Abbott Laboratories (Chicago, IL) and Fresenius AG (Germany).

Bruce S. Colwill is InMed’s CFO. He has more than 25 years of financial leadership experience in public and private companies. Prior to InMed, he served as CFO of General Fusion Inc., a private clean energy company. He was also CFO at Entrée Resources Inc., a mineral exploration company, from 2011 to 2016. He has held CFO roles at Neuromed Pharmaceuticals Ltd., Response Biomedical Corp, Forbes Medi-Tech Inc. and Euronet Worldwide Inc.

Alexandra D.J. Mancini is Senior Vice President, Clinical and Regulatory Affairs at InMed. She has more than 30 years of global biopharmaceutical research and development experience. She has been an executive with numerous biotech companies, including senior vice president of Clinical and Regulatory Affairs at Sirius Genomics; senior vice president of Clinical and Regulatory Affairs at INEX Pharmaceuticals; and vice president of Regulatory Affairs at QLT Inc.

Eric C. Hsu is Senior Vice President, Pre-Clinical Research and Development at InMed. He joined InMed with more than 18 years of scientific leadership experience in the field of gene therapy. He has held various positions within enGene Inc., including vice president of Research and vice president of Scientific Affairs and Operations. He received his Doctorate from the Department of Medical Biophysics at the University of Toronto.

Michael Woudenberg is Vice President, Chemistry, Manufacturing and Controls at InMed. He has more than 20 years of successful drug development, process engineering, GMP manufacturing and leadership experience. He has held positions with 3M, Cardiome Pharma, Arbutus Biopharma and, most recently, was Managing Director of Phyton Biotech LLC.

InMed Pharmaceuticals Inc. (INM), closed Tuesday's trading session at $1.77, off by 0.561798%, on 1,286,842 volume with 3,087 trades. The average volume for the last 3 months is 1.287M and the stock's 52-week low/high is $1.2545/$6.42.

Recent News

LQwD FinTech Corp. (TSX.V: LQWD) (OTCQB: LQWDF)

The QualityStocks Daily Newsletter would like to spotlight LQwD FinTech Corp. (TSX.V: LQWD) (OTCQB: LQWDF).

  • LQwD’s proprietary, multi-pronged Lightning Network platform provides easier access to a decentralized network and payment solution
  • The platform makes it possible for users to create and manage Lightning Network nodes easily; make transactions securely, privately, and almost instantaneous; create channels on the Network with effective routing; request and manage liquidity more efficiently
  • Bitcoin experts have predicted that the price of the cryptocurrency will continue to climb through 2021, potentially hitting highs around USD$80,000 before surging to USD$250,000 by 2025 and a goal of USD$5 million per Bitcoin by 2030
  • The Lightning Network is a second-layer protocol sitting above the Bitcoin blockchain and will advance Bitcoin from a store-of-value to a global monetary network through payment utility. LQwD expects the Network to increase the growing number of active blockchain wallets by increasing Bitcoin scalability, transaction speeds and lowering fees

LQwD FinTech (TSX.V: LQWD) (OTCQB: LQWDF), a financial technology company with a mission of developing institutional-grade services that support the Lightning Network and drive improved functionality, transaction capability, user adoption, and the utility and scalability of Bitcoin, has announced the launch of its proprietary multi-pronged, Lightning Network Software as a Service (SaaS) – LQwD.tech. The platform provides easier access to a decentralized network and payment solution. This SaaS will allow B2B markets, investors, and others to gain broader access, more efficient liquidity, and seamless usage of the global payments infrastructure. The platform creates the potential for multiple nodes across channels, with the potential to lower transaction fees and a more user-friendly option (https://ccw.fm/7epJg).

LQwD FinTech Corp. (TSX.V: LQWD) (OTCQB: LQWDF) is a financial technology company focused on creating enterprise-grade infrastructure to drive bitcoin adoption.

LQwD FinTech’s mission is to develop institutional-grade services that support the Lightning Network and drive improved functionality, transaction capability, user adoption and utility, and scaling of bitcoin. LQwD is also securing a substantial position in bitcoin as an operating asset and will use its holdings to establish nodes and payment channels on the Lightning Network.

The Lightning Network is a second-layer protocol, sitting above the bitcoin blockchain, intended to facilitate faster micro-transactions and lower fees on bitcoin transactions, thus allowing mass adoption of bitcoin.

LQwD expects the Lightning Network to eclipse the patchwork of legacy financial networks that are used to move value today. The company’s software will make migration from legacy networks onto the Lightning Network easy and seamless. By onboarding more financial service providers, LQwD intends to grow the value of the Lightning Network.

The company, formerly known as Interlapse Technologies Corp., is harnessing new payment rails built on top of the bitcoin blockchain that are capable of beyond visa-level transaction volumes and backed by bitcoin, the strongest and most well-known cryptocurrency. These new rails, enabled by the Bitcoin Lightning Network, open a vast opportunity and market segment for digital payments and financial services on a global scale. LQwD aims to leverage its position as a public company to enhance trust in its products and services, and leverage its shares as currency for acquisitions, roll-up and growth, as well as to attract and retain top industry talent.

Product

The Lightning Network is a solution to massively scale the use of bitcoin for microtransactions globally, dramatically improving upon fees, as well as providing instant settlement times. The Lightning Network has experienced explosive growth and is expected to continue with the trend as usage increases. Well-known companies, such as Twitter and Square, have expressed their enthusiasm to incorporate Lightning Network into their platforms. The Lightning Network is scalable, global, open, inclusive, permissionless and decentralized. It is made up of nodes connected via payment channels, and enables off-chain, instantaneous and cheap payments at scale.

Upon launch of LQwD’s Lightning Network platform-as-a-service, users will be able to leverage the Lightning Network infrastructure to send payments instantly, securely and inexpensively anywhere in the world. Companies and service providers will be able to conduct Lightning Network transactions in bitcoin by integrating LQwD’s infrastructure with their business or web property. Connected businesses will be able to easily deploy, monitor and manage LQwD’s Lightning Network nodes with no or low-level technical knowledge required. The company fully expects Lightning Network to be a force for global change and to become the monetary exchange network of the future.

The Lightning Network, which is already built, functioning and growing, will advance bitcoin from a store-of-value to a global monetary network through payment utility. The company expects the Lightning Network will propel the growing number of active blockchain wallets to new heights, by increasing bitcoin’s scalability and lowering its fees for users. For coming generations, everything from wealth to experiences will be acquired and transacted virtually, and LQwD sees the Lightning Network as an enabling technology that can bring bitcoin to hundreds of millions of new users across the globe.

Market Outlook

Forbes in August 2021 noted that “private investors are funding companies that are building the infrastructure that will support future growth of crypto and digital assets,” and called public companies building cryptocurrency infrastructure “the hottest part of the crypto market.” While the first wave of investor interest in crypto firms was directed at companies catering to retail investors, investors have now shifted their attention to infrastructure builders, like LQwD FinTech. Forbes did not put an estimated value on the crypto infrastructure market but pointed out that large-scale adoption of cryptocurrencies will only happen when infrastructure is in place to support it. The larger digital payments market, of which crypto payments are a small fraction, is growing at more than 14 percent annually and is forecast to hit $154 billion by 2025.

Management Team

Shone Anstey is co-founder, chairman and CEO at LQwD FinTech. He has 20 years of experience in building complex technologies and has acted as technology lead for an industrial bitcoin mine and bitcoin mining pool. He is a Certified Cryptocurrency Investigator, and an advisor to the British Columbia Securities Commission. He is also co-founder of BIGG Digital Assets (OTCQX: BBKCF) and took that company public in 2017.

Barry MacNeil is CFO at LQwD FinTech. He is a member of the Chartered Professional Accountants of British Columbia and has more than 30 years of management and accounting experience with public companies and in private practice. His previous positions include director of both public companies and nonprofits, as well as Chief Financial Officer and Corporate Controller.

Albert Szmigielski is co-founder and CTO at LQwD FinTech. He was formerly the Head of Research and Chief Blockchain Engineer at Blockchain Intelligence Group and VP Research at CipherTrace. He holds a B.Sc. in Computing Science from Simon Fraser University, and a Master of Science in Digital Currencies and Blockchain Technologies from the University of Nicosia, Cyprus.

LQwD FinTech Corp. (LQWDF), closed Tuesday's trading session at $0.4428, off by 0.283745%, on 38,800 volume with 23 trades. The average volume for the last 3 months is 38,800 and the stock's 52-week low/high is $0.25/$4.00.

Recent News

Red White & Bloom Brands Inc. (CSE: RWB) (OTCQX: RWBYF)

The QualityStocks Daily Newsletter would like to spotlight Red White & Bloom Brands Inc. (OTCQX: RWBYF).

  • Red White & Bloom Brands is building a multi-state operation in the cannabis and hemp industries through state subsidiaries focused on markets in Florida, Michigan, Illinois, Arizona and California
  • The company is now rapidly building up its cultivation and retail operations in Florida, advancing from regulatory approval in the state last month to the startup of growing activity to supply existing and soon-to-open dispensaries in four cities from Miami to Daytona Beach and across to Spring Hill
  • Florida is on the verge of a “massive medical marijuana boom” as the pain-conscious retirement community grows and residents’ attitudes overwhelmingly favor openness toward legal medical marijuana
  • Red White & Bloom is also putting together a strong retail cannabis position in Michigan and Florida

Multistate cannabis sector operator Red White & Bloom Brands (CSE: RWB) (OTCQX: RWBYF) is off to a quick start in building its high-quality flower resource for product inventory at dispensaries throughout Florida.

Red White & Bloom Brands Inc. (CSE: RWB) (OTCQX: RWBYF) is a torchbearer blazing a new frontier in American cannabis by adhering to the highest ethical, manufacturing, educational, branding and employment standards available in the industry.

Red White & Bloom is a super state operator, leveraging a sizable footprint to dominate the areas in which it operates. CEO Brad Rogers and other management members have seen the struggles of multi-state operators who have spread themselves too thin, which is why Red White & Bloom is intent on dominating each state it enters before expanding further.

Although targeting individual states in the United States, the company is headquartered in Toronto, Canada. Red White & Bloom was established after privately held MichiCann Medical Inc. merged with publicly traded Tidal Royalty in 2019.

Brands

Red White & Bloom has entered strategic brand acquisitions and partnerships aimed at helping the company expand its presence and position as one of the largest players in the United States cannabis market. Red White & Bloom is always diligently searching for brands to acquire that will provide additional value to the company and expand its national footprint.

The company’s current brand portfolio includes:

  • Platinum Premium Cannabis Products (PV): Platinum uses innovative thinking, honesty and responsibility to remain at the forefront of the cannabis industry. PV holds itself and its partners to the highest standards, providing clean and safe CBD and THC products. In the company’s press release dated January 13, 2021, it reported system-wide sales of Platinum-branded products exceeding $2.8 million for the first week of January alone.
  • High Times®: In June 2020, the company acquired the licensing rights and branding of High Times dispensaries and High Times cannabis-based CBD and THC products in Michigan, Illinois and Florida. The company also acquired branding of High Times hemp derived CBD products nationally in the United States carrying the Culture® brand.
  • Mid-American Growers: Mid-American began as a family operation in 1971 in Granville, Illinois. The original 8-acre greenhouse has expanded to a 3.6-million-square-foot, state-of-the-art technology and science facility under glass. Mid-American’s product offerings include its CBD Icy Relief Salve, CBD Icy Relief Roll-on and CBD Gummies.

Retail Focus

Red White & Bloom is working to establish a significant retail presence across multiple jurisdictions. In Michigan, the company is invested in and has the rights to acquire (subject to regulatory approvals) a licensed operator that controls the assets of 18 dispensary locations throughout the state. Red White & Bloom is also pursuing opportunities in Florida aimed at making its proposed retail footprint compelling and attractive to the majority of cannabis consumers within each state.

Cultivation

Red White & Bloom is focused on standardization and quality, with everything guided by a relentless commitment to the highest standards. The company acquired a 3.6-million-square-foot standardized facility dedicated to helping it achieve premium value for the products it intends to cultivate.

As it continues to expand, the company remains committed to the practices that have guided its success in the past, including:

  • A top-down approach to cultivation developed under the guidance of PhDs with expertise in growing principles, SOPs and, most importantly, the science behind it all.
  • Commitment to exceeding the requirement of the states in which it operates. The company cut its teeth under the world’s first national cannabis purity regime – a regime that most new markets use as a benchmark – so quality is in its DNA.
  • Science-driven production methods supported by automated, perpetual, standardized operations that enable craft cannabis-like quality at an industrial scale.

Footprint

Assuming completion of the currently proposed investments and acquisitions, Red White & Bloom will be among the cannabis market’s largest companies, joining the ranks of a select few multi-state operators dominating the industry. Red White & Bloom currently has assets (closed and in closing stages) in Michigan, Illinois, Florida, California, Oklahoma and Massachusetts.

The company’s strategic acquisition and super state operator model, combined with its commitment to top-quality product and service, position it to become a leading player in the North American cannabis market.

When evaluated beside competitors in the cannabis space, Red White & Bloom boasts an extremely attractive valuation. While large cap cannabis firms serving North American markets averaged enterprise-value-to-EBITDA multiples of 14.9x as of December 2020, Red White & Bloom’s enterprise multiple was just 3.4x, as noted in the company’s latest investor deck.

In 2020, the cannabis market worldwide was valued at $24.6 billion. This amount is expected to expand at a CAGR of 14.3% from 2021 to 2028, resulting in a market size of $84 billion in 2028 (https://nnw.fm/f09ZL). Of the 2020 valuation, the largest revenue share (91.1%) was attributed to North American consumers (https://nnw.fm/vObW6).

Management Team

Brad Rogers is the CEO and Executive Chair of Red White & Bloom. He is a visionary for the future of cannabis and CBD products in the United States market, with a proven track record of building successful and profitable businesses in the rapidly expanding and new economic sector. Mr. Rogers was a part of the team that built one of the first commercially scaled production facilities in the world for medicinal cannabis. He also served as President for one of the leading licensed producers in Canada. Both of his ventures were successful, with a combined market cap of $2 billion.

Michael Marchese is the company’s Co-Founder and Marketing Advisor. He has played a crucial role in its development and organization, overseeing capital raises, acquisition strategy and brand identity. Mr. Marchese has a strong reputation and presence in the cannabis industry. He also co-founded and directed the branding of Aleafia Health Inc., which he continues to counsel. Through his branded company, Marchese Design, he has served as a highly trusted counselor to top-level execs, including C-Suite level employees, offering insights into the process of creating, building and maintaining brand identities.

Theo van der Linde is the CFO and Director of Red White & Bloom. He is a Chartered Accountant with 20 years of experience in finance, administration and public accounting. The experience he has acquired spans multiple industries, including mining, oil & gas, financial services, retail and manufacturing. For the last nine years, he has primarily focused his career on the mining industry, working with junior exploration and producing mining companies at various stages of growth in several jurisdictions. Mr. van der Linde is also the current President of Executive Management Solutions Ltd.

Red White & Bloom Brands Inc. (RWBYF), closed Tuesday's trading session at $0.44, off by 3.2967%, on 355,032 volume with 120 trades. The average volume for the last 3 months is 355,032 and the stock's 52-week low/high is $0.405/$1.65.

Recent News

Avricore Health Inc. (TSX.V: AVCR) (OTCQB: AVCRF)

The QualityStocks Daily Newsletter would like to spotlight Avricore Health Inc. (OTCQB: AVCRF).

Avricore Health (TSX.V: AVCR) (OTCQB: AVCRF) today announced that its wholly owned subsidiary, HealthTab(TM), has entered into a non-exclusive, pilot supplier distribution agreement in Canada with Abbott, the global health care company, with respect to the handheld blood chemistry analyzer, i-STAT Alinity. Under the agreement, HealthTab will distribute Abbott’s point-of-care i-STAT Alinity and its associated tests for creatinine in Canadian pharmacies to better support patients with important information about their renal function. “Understanding renal function in patients at risk from or already living with chronic disease is critical,” said Hector Bremner, CEO of Avricore Health. “With i-STAT Alinity and its associated test for creatinine, health care professionals can obtain results in approximately two minutes to detect elevated levels of creatinine that are associated with abnormal renal function.” To view the full press release, visit: https://ibn.fm/TIUHn

Avricore Health Inc. (TSX.V: AVCR) (OTCQB: AVCRF) is a pharmacy service innovator focused on acquiring and developing early-stage technologies aimed at moving pharmacy forward. Through its flagship offering, HealthTab™ (a wholly owned subsidiary), the company aims to make actionable health information more accessible to everyone by creating the world’s largest network of rapid testing devices in community pharmacies.

HealthTab

HealthTab is a turnkey point-of-care testing solution that effectively turns pharmacies into diagnostic hubs (sometimes known as ‘Community Diagnostic Centers’, or CDCs) and connects them on a single, cloud-based platform.

The HealthTab network model is unlike anything in pharmacy today. It gives knowledgeable and trusted pharmacists a greater role in primary care delivery and empowers patients to take more control of their health. It also reduces costs and waiting times while providing many potential revenue streams, including equipment leasing & consumables, direct access testing, disease prevention & management programs, sponsored health programs, decentralized clinical trials, real world data (RWD) sets and third-party app integration through API.

Agreement with Shoppers Drug Mart

In June 2021, Avricore signed a Master Agreement with select Shoppers Drug Mart pharmacies to pilot the HealthTab platform. This agreement gives patients access to point-of-care blood screening and health-data management for potential risks relating to diabetes and cardiovascular conditions using HealthTab-integrated Afinion 2™ analyzers provided by Abbott Rapid Diagnostics.

Avricore is the first pharmacy solutions provider to partner with Abbott (NYSE: ABT), the global health care company and diagnostics leader in Canada. In May 2021, the company signed a supplier distribution agreement to expand the distribution of Abbott’s Afinion 2 and associated tests for diabetes and heart disease screening in community pharmacies in Canada. This agreement includes valuable HbA1c testing, a critical marker for the screening and management of diabetes.

Near Term Goals

Near term goals for Avricore include expansion into more pharmacies across Canada, followed soon after by entering the U.S. and UK markets. The company has made significant strides in testing and developing its technology and is moving into the commercialization stage.

Strategic partnerships like those with Abbott and select Shoppers Drug Mart pharmacies advance Avricore closer to becoming an incredibly dominant player in the community diagnostics space. The company aims to make actionable health information more accessible for everyone by creating the world’s largest rapid testing network in pharmacies.

Market Outlook

In 2020, the global point-of-care testing (POCT) market was valued at $34.49 billion and expected to expand at a compound annual growth rate (CAGR) of 9.4 percent to reach a projected $81.37 billion by 2028. This upsurge is expected to be driven largely by increased demand for screening and management tools for chronic diseases, as well as rapidly assessing infectious diseases such as COVID-19.

The accessibility of POCT has been an increasing priority of the world’s leading health organizations and experts. Pharmacies are ideal ‘hubs’ within the community to offer patients better access to the numbers they need to know for preventing or treating conditions such as diabetes and heart disease or the timely diagnosis of infection.

Management Team

Avricore’s leadership team brings a diverse portfolio of expertise across the health care and biotech industries, as well as technology, finance and communications. Together, they share a common vision of moving pharmacy forward and have positioned the company for significant future growth and expansion.

Hector Bremner is the CEO of Avricore. He has over 15 years of senior and executive experience across various industries, including international trade, natural gas, marketing and communications. He owned and operated TOUCH Marketing, a boutique marketing and communications firm based in Vancouver, from 2007 to 2013. Mr. Bremner has also served as the executive assistant to the Deputy Premier and Minister of Natural Gas Development, Responsible for Housing, as well as the Minister of International Trade and Minister of Small Business. In 2015, he joined Vancouver’s Pace Group Communications as VP of Public Affairs.

David Hall is the Chairman and a Director of Avricore. His leadership spans five different companies. He is currently the Chairman of RepliCel Life Sciences and a member of the boards of TrichoScience Innovations, AdvantageBC and Providence Health Care Research Institute. Mr. Hall also served as Chairman of Perceptronix Medical Inc.; Chief Financial Officer, Secretary & Treasurer of Angiotech Pharmaceuticals Inc.; President & Director at Newcastle Resources Ltd.; and Chairman for LifeSciences British Columbia.

Kiki Smith is Avricore’s CFO. She has over 20 years of experience assisting private and public companies in the roles of accountant, corporate controller and CFO in mining, oil & gas, real estate, high technology, food production and investment fund management. She currently provides consulting services in M&A, financial reporting and regulatory compliance to several public and private companies across several investment sectors. Ms. Smith is a member of the Chartered Professional Accountants of British Columbia and has a bachelor’s degree in economics from the University of British Columbia.

Rodger Seccombe is the Head of Avricore’s HealthTab division and the co-founder and former CEO of HealthTab Inc. Mr. Seccombe has over 20 years of experience launching and running companies in software, health care technology and clean energy. He is a recognized industry expert in direct-to-consumer and point-of-care testing technology. In 2006, he joined the start-up team at Canadian Bioenergy Corporation and helped pioneer the development of the renewable fuel industry in Canada. Before HealthTab, he designed and developed cloud-based informatics systems currently in use by some of the world’s leading medical laboratories and instrument manufacturers.

Avricore Health Inc. (OTCQB: AVCRF), closed Tuesday's trading session at $0.1171, off by 3.3031%, on 100 volume with 1 trade. The average volume for the last 3 months is 100 and the stock's 52-week low/high is $0.068/$0.48562.

Recent News

Friendable Inc. (FDBL)

The QualityStocks Daily Newsletter would like to spotlight Friendable Inc. (FDBL).

  • Rositano Jr. is looking for the Fan Pass Live artist platform to expand its global reach and become a household name in the near future
  • The live interview put Fan Pass into the spotlight and introduced the platform to Hype’s estimated audience of 300,000 readers and its social media following of over 484k on Instagram and over 189k on Twitter
  • Rositano Jr. made it clear during the interview that great things are planned from Friendable for the Fan Pass platform in the new year

Music has always found a place in the lives of Robert A. Rositano Jr. and his brother (and business partner) Dean. Growing up, Dean was a touring musician, and as a family, the Rositanos have always been enchanted by artists and the music industry. In a recent interview with The Hype Magazine, Rositano Jr., the CEO of Friendable (OTC: FDBL), sat down for a live discussion with the magazine’s Editor-in-Chief, Jerry Doby, to discuss his company’s innovative artist streaming platform, from inception to plans for the future (https://ibn.fm/Vu4bs).

Friendable Inc. (FDBL) is a mobile technology and marketing company focused on connecting and engaging users through its proprietary mobile and desktop applications. Launched July 24, 2020, the company’s flagship offering is designed to help artists engage with their fans around the world and earn revenue while doing so. The livestreaming platform supports artists at all levels, providing exclusive artist content ‘Channels’, LIVE event streaming, promotional support, fan subscriptions and custom merchandise designs, all of which serve as revenue streams for each artist.

With Fan Pass, artists can offer exclusive content channels to their fans, who can use their smartphones to gain access to their favorite artists, as well as an all-access pass to all artists on the platform. Additionally, the Fan Pass team will deploy social broadcasters to capture exclusive VIP experiences, interviews and behind-the-scenes content featuring their favorite artists – all available to fan subscribers on a free trial basis. Subscriptions are billed monthly at $3.99, or about the cost of downloading a couple of songs, and VIP experiences are available at a fraction of the cost of traditional face-to-face meetups.

Friendable Inc. was founded by Robert A. Rositano Jr. and Dean Rositano, two brothers with over 27 years of experience working together on technology-related ventures.

The Fan Pass Mobile & Desktop App

Friendable Inc. launched its Fan Pass platform as a solution for artists and their fans as the COVID-19 pandemic and the associated shutdown have continued to severely hamstring the entertainment industry as a whole. Through Fan Pass, the company aims to reach artists at all levels looking to alter their touring schedules to include ‘Virtual Touring’, new revenue sources and innovative fan engagement opportunities that are expected to become permanent fixtures of artists’ touring routines moving forward.

Fan Pass creates an ecosystem that embraces fans of all kinds, feeding diehard followers and developing lasting connections with more casual supporters. Through the app, qualified artists are provided with a custom designed, exclusive ’Fan Pass Channel’ where they can invite fans and social followers from anywhere around the world to join in chats and live events – allowing fans to experience all there is to see of an artist in one place. Artists earn revenue from monthly fan subscribers, merchandise sales, tickets sold for virtual streaming events and generally from all content views or impressions on their channels. All content views and sales of every kind are reported to each artist through their dashboards, including real-time payout and earnings information.

Fan Pass’ exclusive ‘All Access VIP’ option provides fans with access to content, such as:

  • Live performances or online concerts
  • Backstage meetups before, during or after events
  • Livestreams of studio sessions
  • Behind-the-scenes footage of music video and photo shoots
  • Special interviews and one-on-one videos
  • Streams highlighting the artists’ daily lives

The Fan Pass platform is extremely intuitive, bringing each artist through a streamlined onboarding process, including building out artist ‘Channels’, scheduling LIVE events and designing special edition merchandise to be offered solely through exclusive Fan Pass merchandise stores.

“With the global pandemic disrupting the entertainment industry in such a profound way, artists have had to look to digital distribution and live virtual performances in order to maintain any earning opportunities. Fan Pass and our team are determined to provide solutions and support to all artists, their fans and the industry in general. We are excited about the opportunity we have to shape the future of virtual entertainment, revenue generation and artist/fan engagement,” Robert A. Rositano Jr., CEO of Friendable Inc., stated in a news release.

Market Opportunity

Artists rely heavily on revenue streams that are not often seen by those without intimate industry knowledge. When it comes to traditional performances, the sale of VIP/backstage or meet & greet passes to boost revenue can often become the majority of the artist’s annual tour revenue. Data provided by one of the company’s original entertainment partners, The Kluger Agency (TKA), suggests that as much as 18-23% of artists’ annual tour revenue has historically been derived from these VIP experiences.

The World Economic Forum reports that, in 2020, the six-month-plus disappearance of live music concerts is estimated to have cost “the industry more than $10 billion in sponsorships,” and individual artists are feeling the loss the most. Fan Pass is helping to bridge this gap, providing more affordable virtual VIP experiences that can be offered simultaneously to fans around the world.

While it’s free for artists to join, Fan Pass leverages a monthly subscription model paid by fans to generate revenues. These revenues are shared with all channel artists. In exchange for its platform features, live streaming tools, bandwidth, processing and handling, Fan Pass earns platform fees on each separately ticketed event, as well as splits with each artist on subscriber fees and merchandise designed and sold on the platform.

The U.S. video streaming industry is expected to hit $7.08 billion in value in 2021, with an estimated 100 million internet users watching online video content every day, according to data from Livestream.com. The same report suggests that 45% of live video audiences would pay for exclusive, on-demand video from a favorite team, speaker or performer. Through Fan Pass, Friendable Inc. is uniquely positioned to capitalize on this opportunity.

Friendable App

The company’s second application, Friendable, is an all-inclusive platform where users can meet, chat and date. The app has exceeded 1.5 million total downloads, with over 900,000 historical registered users and more than 580,000 historical user profiles.

Friendable Inc.’s Next Phase of Growth

To facilitate its next phase of growth, Friendable Inc. is seeking an additional $1 million in equity investment, with a follow-on funding that meets or exceeds $5 million. The company intends to utilize its relationships to secure the lowest cost of capital available, as these funds will drive technology advancements, increase head count, fund marketing initiatives and secure additional celebrity talent aimed at bringing larger fan audiences to each released event. These initiatives will assist in building recurring monthly (fan) subscribers, effectively generating recurring monthly revenue for each artist, as well. The next phase of growth is expected to play a key role in accelerating the company’s download and conversion of data for subscription revenue and merchandise sales.

The company’s primary goal is to establish Fan Pass as a premier brand and mobile platform dedicated to connecting and engaging users around the world. In support of this goal, it has entered into a partnership with Brightcove targeting OTT platform expansion, including leaders such as iOS, Android, Apple TV, Android TV, Roku and WWW.

In the highly competitive video streaming market, Friendable Inc. has tapped into an unmet demand from today’s ever-present ‘omni-users’ for constant contact with celebrities and influencers. Via Fan Pass, the company offers investors an opportunity to gain a stake in an organization catering to this new breed of omni-users and their influencers.

The application’s potential is clearly illustrated by the interest it has generated in recent weeks. From September 4 to October 12, the Fan Pass platform added 246 new artists, accounting for a 410 percent increase in just six weeks.

“We are extremely encouraged by the ongoing swell of interest as the value of our Fan Pass platform continues to resonate in the artist community,” Friendable CEO Robert A. Rositano Jr. stated in a news release. “We believe the live streaming functionality, our full-circle offering and diverse revenue opportunities the platform offers will continue to drive exponential growth as management remains focused on building long-term shareholder value.”

Management Team

Robert A. Rositano Jr. is the co-founder and CEO of Friendable Inc. He oversees the daily management and operational duties of all areas of the business. He has over 20 years of experience as a serial entrepreneur, bringing in over $60 million in liquidity events for the companies he has created or managed. Before starting Friendable Inc. with his brother, Rositano was a founding member of the internet’s first IPO, Netcom Online Communications Inc. It was sold to ICG, then to EarthLink in 1995. He has been a co-founder of several successful ventures, including Simply Internet Inc., Nettaxi.com and America’s Biggest Inc., among others. He also authored one of the first web directories for MacMillan Publishers.

Dean Rositano is the co-founder and Chief Technology Officer of Friendable Inc. He handles the day-to-day operations and guides the technical direction of the company. He has over 15 years of executive management, financial management, high technology operations and internet architecture experience. Before co-founding Friendable Inc., Rositano co-founded several other companies, including Checkmate Mobile Inc. and Latitude Venture Partners LLC, among others.

Friendable Inc. (FDBL), closed Tuesday's trading session at $0.0046, off by 8%, on 1,195,461 volume with 33 trades. The average volume for the last 3 months is 1.195M and the stock's 52-week low/high is $0.0037/$0.0979.

Recent News

Sugarmade, Inc. (OTC: SGMD)

The QualityStocks Daily Newsletter would like to spotlight Sugarmade, Inc. (OTC: SGMD).

Sugarmade (OTC: SGMD), an innovator in the dynamic California cannabis sector, is among companies welcoming Assembly Bill 45 (“AB-45”). The bill went into effect recently, creating a comprehensive regulatory framework for the manufacture and sale of hemp-derived products in California and setting a new focus on safety and consistency. Sugarmade is a California-based company that is committed to providing high-quality products and excellent services. “Sugarmade is a majority owner and operator (70%) of Nug Avenue, a cannabis-delivery services brand based in southern California that offers hand-selected, top-shelf products. The company is committed to providing convenient mobile ordering and online access to its exclusive, quality products,” reads a recent article, which contains excerpts from a High Times news report detailing the AB-45 legislation. “While CBD products are freely found in stores, they are considered ‘adulterated’ under existing California law, which is defined under the Sherman Food, Drug and Cosmetic Law,” stated the High Times publication. “What AB-45 will do is provide clarity for the hemp industry — more importantly, reassuring hemp consumers that products are independently tested and labeled properly.” To view the full article, visit https://cnw.fm/ggrTh

Sugarmade, Inc. (OTC: SGMD) is a product and brand marketing company investing in operations and technologies with disruptive potential. The company is focused on collaborating with real people in real-time to identify the emerging desires and behaviors poised to unlock new opportunities and pathways for growth. Sugarmade seeks to redefine the marketplace by nurturing an innovative and compelling relationship between brand, botany and business – resulting in both undeniable consumer value and an intriguing cross-pollination of revenue sources.

The company’s core strategic plan is centered on expanding its end-market access as a central player in the growing California cannabis delivery marketplace while developing its in-house cannabis production capacity to verticalize operations in the space. Through a combination of organic growth and strategic acquisitions, Sugarmade intends to develop a full farm-to-door vertically integrated cannabis business.

Brand Portfolio

Sugarmade has investments in a number of subsidiaries with active operations in the California cannabis sector. These include:

  • NUG Avenue – Sugarmade owns a 70% stake in NUG Avenue, a cannabis delivery service based in Southern California providing hand-selected top-shelf products from Stiiizy, Kanha, PlugPlay and more.
  • BudCars – Sugarmade is an investor in cannabis delivery service of BudCars’ first operating location in Sacramento, California. BudCars is an online-shopping experience designed to provide new customers with an easy way to discover and order cannabis products within minutes.

Acquisition of Lemon Glow Company

On May 17, 2021, Sugarmade took a major step toward closing the loop on what its management team believes to be one of the most promising vertically integrated cannabis models in the thriving California market when it announced the signing of a definitive agreement for its acquisition of Lemon Glow Company Inc.

The Lemon Glow acquisition includes 640 acres of property, 32 of which have already been designated for outdoor cannabis cultivation. Per the company’s news release, the annual potential cultivation yield at the property is estimated to be approximately 4,000 pounds of dry trimmed cannabis flower per acre per year, which represents approximately 128,000 pounds, or 64 tons, of dry trimmed cannabis flower per year in total.

Notably, Sugarmade also benefits from the acquisition in terms of team capital, as Lemon Glow executive team members will stay on and become the core management team at the cannabis cultivation site, granting the operation over 30 years of cannabis cultivation experience.

“The Lemon Glow team are tremendous additions to the Sugarmade team,” Jimmy Chan, CEO of Sugarmade, commented in announcing the definitive agreement. “They have vast experience and established skills, as well as intricate knowledge of the property and its local grow context. That’s an enormous added value proposition in this deal. We look forward to bringing them on board, ramping up operations at the property, and taking key steps toward delivering on the promise of Sugarmade’s farm-to-door vision.”

Market Opportunity

The California cannabis industry has continued to record tremendous growth since voters approved a measure to legalize recreational use of the plant in 2016. According to data from MJBizDaily, California’s legal market hit $4.4 billion in sales in 2020, up from $2.8 billion in 2019 and $1.4 billion in 2018.

Those figures highlight California’s status as the largest legal cannabis market in the world. With roughly 28 million residents over the age of 21, California is more than twice the combined size of the four states (Arizona, New Jersey, Montana and North Dakota) that legalized cannabis in 2020.

The COVID-19 pandemic was a key driver in the growth of cannabis delivery services throughout the state in 2020. One California cannabis delivery firm reported a 60% increase in new delivery customer sign-ups in the 30 days following the March 13, 2020, declaration of a national emergency. As a result of this boom, tech companies in cannabis ecommerce were able to dramatically increase their market share.
Sugarmade’s continued efforts to develop a farm-to-door vertically integrated cannabis business position it to capitalize on these trends as the California cannabis industry continues to expand moving forward.

Management

Jimmy Chan is the CEO of Sugarmade. He is an experienced business executive instrumental in growing multiple business operations with a strong expertise in international trade and banking, international manufacturing and importation. He is also the founder of CarryOutSupplies.com, a company that revolutionized the custom-printed paper supplies subsector of the quick service restaurant industry, which merged with Sugarmade in 2014.

Sugarmade, Inc. (OTC: SGMD), closed Tuesday's trading session at $0.00125, off by 7.4074%, on 61,043,971 volume with 189 trades. The average volume for the last 3 months is 61.044M and the stock's 52-week low/high is $0.0007/$0.02.

Recent News

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

closed Wednesday's trading